The	O
Epstein-Barr	B-DNA
virus	I-DNA
promoter	I-DNA
initiating	O
B-cell	O
transformation	O
is	O
activated	O
by	O
RFX	B-protein
proteins	I-protein
and	O
the	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
BSAP/Pax5	I-protein
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-induced	O
B-cell	B-cell_type
growth	O
transformation	O
,	O
a	O
central	O
feature	O
of	O
the	O
virus	O
'	O
strategy	O
for	O
colonizing	O
the	O
human	O
B-cell	O
system	O
,	O
requires	O
full	O
virus	O
latent	O
gene	O
expression	O
and	O
is	O
initiated	O
by	O
transcription	O
from	O
the	O
viral	B-DNA
promoter	I-DNA
Wp	I-DNA
.	O

Interestingly	O
,	O
when	O
EBV	O
accesses	O
other	O
cell	O
types	O
,	O
this	O
growth-transforming	O
program	O
is	O
not	O
activated	O
.	O

The	O
present	O
work	O
focuses	O
on	O
a	O
region	O
of	O
Wp	B-DNA
which	O
in	O
reporter	O
assays	O
confers	O
B-cell	B-cell_type
-specific	O
activity	O
.	O

Bandshift	O
studies	O
indicate	O
that	O
this	O
region	O
contains	O
three	O
factor	O
binding	O
sites	O
,	O
termed	O
sites	B-DNA
B	I-DNA
,	I-DNA
C	I-DNA
,	I-DNA
and	I-DNA
D	I-DNA
,	O
in	O
addition	O
to	O
a	O
previously	O
characterized	O
CREB	B-DNA
site	I-DNA
.	O

Here	O
we	O
show	O
that	O
site	B-DNA
C	I-DNA
binds	O
members	O
of	O
the	O
ubiquitously	O
expressed	O
RFX	B-protein
family	I-protein
of	I-protein
proteins	I-protein
,	O
notably	O
RFX1	B-protein
,	O
RFX3	B-protein
,	O
and	O
the	O
associated	O
factor	O
MIBP1	B-protein
,	O
whereas	O
sites	B-DNA
B	I-DNA
and	I-DNA
D	I-DNA
both	O
bind	O
the	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
BSAP/Pax5	I-protein
.	O

In	O
reporter	O
assays	O
with	O
mutant	B-DNA
Wp	I-DNA
constructs	I-DNA
,	O
the	O
loss	O
of	O
factor	O
binding	O
to	O
any	O
one	O
of	O
these	O
sites	O
severely	O
impaired	O
promoter	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
while	O
the	O
wild-type	B-DNA
promoter	I-DNA
could	O
be	O
activated	O
in	O
non-B	B-cell_type
cells	I-cell_type
by	O
ectopic	O
BSAP	O
expression	O
.	O

We	O
suggest	O
that	O
Wp	B-DNA
regulation	O
by	O
BSAP	B-protein
helps	O
to	O
ensure	O
the	O
B-cell	B-cell_type
specificity	O
of	O
EBV	O
's	O
growth-transforming	O
function	O
.	O

JOURNAL	NULL
OF	NULL
VIROLOGY	NULL
,	NULL
Nov.	NULL
2000	NULL
,	NULL
p.	NULL
10458-10467	NULL
0022-538	NULL
X	NULL
,	NULL
/00/	NULL
$	NULL
04.00+0	NULL
Vol	NULL
.	NULL

74	NULL
,	NULL
No	NULL
.	NULL

22	NULL
Copyright	NULL
©	NULL
2000	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
Virus	NULL
Promoter	NULL
Initiating	NULL
B-Cell	NULL
Transformation	NULL
Is	NULL
Activated	NULL
by	NULL
RFX	NULL
Proteins	NULL
and	NULL
the	NULL
B-Cell-Specific	NULL
Activator	NULL
Protein	NULL
BSAP/Pax5	NULL
ROSEMARY	NULL
TIERNEY	NULL
,	NULL
HELEN	NULL
KIRBY	NULL
,	NULL
JASDEEP	NULL
NAGRA	NULL
,	NULL
ALAN	NULL
RICKINSON	NULL
,	NULL
*	NULL
AND	NULL
ANDREW	NULL
BELL	NULL
CRC	NULL
Institute	NULL
for	NULL
Cancer	NULL
Studies	NULL
,	NULL
University	NULL
of	NULL
Birmingham	NULL
,	NULL
Edgbaston	NULL
,	NULL
Birmingham	NULL
B15	NULL
2TT	NULL
,	NULL
United	NULL
Kingdom	NULL
Received	NULL
5	NULL
June	NULL
2000/Accepted	NULL
18	NULL
August	NULL
2000	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-induced	NULL
B-cell	NULL
growth	NULL
transformation	NULL
,	NULL
a	NULL
central	NULL
feature	NULL
of	NULL
the	NULL
virus	NULL
'	NULL
strategy	NULL
for	NULL
colonizing	NULL
the	NULL
human	NULL
B-cell	NULL
system	NULL
,	NULL
requires	NULL
full	NULL
virus	NULL
latent	NULL
gene	NULL
expression	NULL
and	NULL
is	NULL
initiated	NULL
by	NULL
transcription	NULL
from	NULL
the	NULL
viral	NULL
promoter	NULL
Wp	NULL
.	NULL

Interestingly	NULL
,	NULL
when	NULL
EBV	NULL
accesses	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
this	NULL
growth-transforming	NULL
program	NULL
is	NULL
not	NULL
activated	NULL
.	NULL

The	NULL
present	NULL
work	NULL
focuses	NULL
on	NULL
a	NULL
region	NULL
of	NULL
Wp	NULL
which	NULL
in	NULL
reporter	NULL
assays	NULL
confers	NULL
B-cell-specific	NULL
activity	NULL
.	NULL

Bandshift	NULL
studies	NULL
indicate	NULL
that	NULL
this	NULL
region	NULL
contains	NULL
three	NULL
factor	NULL
binding	NULL
sites	NULL
,	NULL
termed	NULL
sites	NULL
B	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
a	NULL
previously	NULL
characterized	NULL
CREB	NULL
site	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
site	NULL
C	NULL
binds	NULL
members	NULL
of	NULL
the	NULL
ubiquitously	NULL
expressed	NULL
RFX	NULL
family	NULL
of	NULL
proteins	NULL
,	NULL
notably	NULL
RFX1	NULL
,	NULL
RFX3	NULL
,	NULL
and	NULL
the	NULL
associated	NULL
factor	NULL
MIBP1	NULL
,	NULL
whereas	NULL
sites	NULL
B	NULL
and	NULL
D	NULL
both	NULL
bind	NULL
the	NULL
B-cell-specific	NULL
activator	NULL
protein	NULL
BSAP/Pax5	NULL
.	NULL

In	NULL
reporter	NULL
assays	NULL
with	NULL
mutant	NULL
Wp	NULL
constructs	NULL
,	NULL
the	NULL
loss	NULL
of	NULL
factor	NULL
binding	NULL
to	NULL
any	NULL
one	NULL
of	NULL
these	NULL
sites	NULL
severely	NULL
impaired	NULL
promoter	NULL
activity	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
while	NULL
the	NULL
wild-type	NULL
promoter	NULL
could	NULL
be	NULL
activated	NULL
in	NULL
non-B	NULL
cells	NULL
by	NULL
ectopic	NULL
BSAP	NULL
expression	NULL
.	NULL

We	NULL
suggest	NULL
that	NULL
Wp	NULL
regulation	NULL
by	NULL
BSAP	NULL
helps	NULL
to	NULL
ensure	NULL
the	NULL
B-cell	NULL
specificity	NULL
of	NULL
EBV	NULL
's	NULL
growth-transforming	NULL
function	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
is	NULL
the	NULL
best	NULL
known	NULL
of	NULL
the	NULL
y1	NULL
her-pesviruses	NULL
,	NULL
a	NULL
group	NULL
of	NULL
closely	NULL
related	NULL
B-lymphotropic	NULL
agents	NULL
of	NULL
primates	NULL
which	NULL
have	NULL
evolved	NULL
a	NULL
unique	NULL
strategy	NULL
through	NULL
which	NULL
to	NULL
access	NULL
,	NULL
disseminate	NULL
,	NULL
and	NULL
persist	NULL
within	NULL
the	NULL
B-lymphoid	NULL
system	NULL
.	NULL

The	NULL
essential	NULL
features	NULL
of	NULL
that	NULL
strategy	NULL
are	NULL
threefold	NULL
.	NULL

First	NULL
,	NULL
EBV	NULL
can	NULL
efficiently	NULL
access	NULL
target	NULL
B	NULL
lymphocytes	NULL
through	NULL
an	NULL
interaction	NULL
between	NULL
the	NULL
major	NULL
viral	NULL
envelope	NULL
glycoprotein	NULL
gp340	NULL
and	NULL
the	NULL
complement	NULL
receptor	NULL
CR2/CD21	NULL
,	NULL
a	NULL
cell	NULL
surface	NULL
molecule	NULL
expressed	NULL
preferentially	NULL
though	NULL
not	NULL
exclusively	NULL
on	NULL
B-lymphoid	NULL
cells	NULL
(	NULL
16	NULL
,	NULL
38	NULL
,	NULL
57	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
virus	NULL
carries	NULL
a	NULL
set	NULL
of	NULL
latent	NULL
cycle	NULL
genes	NULL
,	NULL
encoding	NULL
six	NULL
nuclear	NULL
antigens	NULL
(	NULL
EBNA1	NULL
,	NULL
EBNAZ	NULL
,	NULL
EBNA3A	NULL
,	NULL
EBNA3B	NULL
,	NULL
EBNA3C	NULL
,	NULL
and	NULL
EBNA-LP	NULL
)	NULL
and	NULL
three	NULL
latent	NULL
membrane	NULL
proteins	NULL
(	NULL
LMP1	NULL
,	NULL
LMP2A	NULL
,	NULL
and	NULL
LMP2B	NULL
)	NULL
,	NULL
whose	NULL
coordinate	NULL
expression	NULL
in	NULL
newly	NULL
infected	NULL
B	NULL
cells	NULL
activates	NULL
cell	NULL
growth	NULL
(	NULL
26	NULL
)	NULL
;	NULL
this	NULL
growth	NULL
transformation	NULL
,	NULL
first	NULL
observed	NULL
in	NULL
vitro	NULL
,	NULL
where	NULL
experimental	NULL
infection	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
leads	NULL
to	NULL
the	NULL
outgrowth	NULL
of	NULL
permanent	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
,	NULL
is	NULL
also	NULL
seen	NULL
during	NULL
primary	NULL
EBV	NULL
infection	NULL
in	NULL
vivo	NULL
as	NULL
a	NULL
virus-driven	NULL
expansion	NULL
of	NULL
the	NULL
latently	NULL
infected	NULL
B-cell	NULL
pool	NULL
(	NULL
58	NULL
)	NULL
.	NULL

Third	NULL
,	NULL
following	NULL
this	NULL
expansion	NULL
,	NULL
the	NULL
transforming	NULL
program	NULL
of	NULL
latent	NULL
gene	NULL
expression	NULL
can	NULL
be	NULL
down-regulated	NULL
in	NULL
vivo	NULL
as	NULL
the	NULL
infected	NULL
cells	NULL
move	NULL
out	NULL
of	NULL
cycle	NULL
and	NULL
enter	NULL
the	NULL
resting	NULL
memory	NULL
B-cell	NULL
pool	NULL
(	NULL
3	NULL
,	NULL
35	NULL
,	NULL
43	NULL
)	NULL
;	NULL
the	NULL
latter	NULL
is	NULL
the	NULL
reservoir	NULL
upon	NULL
which	NULL
successful	NULL
virus	NULL
persistence	NULL
in	NULL
the	NULL
immune	NULL
host	NULL
appears	NULL
to	NULL
depend	NULL
.	NULL

This	NULL
report	NULL
concerns	NULL
the	NULL
mechanisms	NULL
whereby	NULL
EBV	NULL
specifically	NULL
activates	NULL
its	NULL
growth-transforming	NULL
program	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

In	NULL
experimentally	NULL
infected	NULL
B	NULL
cells	NULL
,	NULL
the	NULL
first	NULL
viral	NULL
transcripts	NULL
are	NULL
driven	NULL
from	NULL
a	NULL
viral	NULL
promoter	NULL
,	NULL
Wp	NULL
,	NULL
localized	NULL
within	NULL
the	NULL
BamHI	NULL
W	NULL
repeat	NULL
region	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
(	NULL
2	NULL
,	NULL
64	NULL
)	NULL
.	NULL

These	NULL
transcripts	NULL
lead	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
two	NULL
nuclear	NULL
antigens	NULL
,	NULL
EBNAZ	NULL
and	NULL
EBNA-LP	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
critical	NULL
for	NULL
efficient	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
CRC	NULL
Institute	NULL
for	NULL
Cancer	NULL
Studies	NULL
,	NULL
University	NULL
of	NULL
Birmingham	NULL
,	NULL
Edgbaston	NULL
,	NULL
Birmingham	NULL
B15	NULL
2IT	NULL
,	NULL
United	NULL
Kingdom	NULL
.	NULL

Phone	NULL
:	NULL
44-121-414-4492	NULL
.	NULL

Fax	NULL
:	NULL
44-121-414-4486	NULL
.	NULL

E-mail	NULL
:	NULL
A.B.Rickinson	NULL
@	NULL
bham.ac.uk	NULL
.	NULL

transformation	NULL
.	NULL

EBNAZ	NULL
,	NULL
acting	NULL
alone	NULL
or	NULL
in	NULL
cooperation	NULL
with	NULL
EBNA-LP	NULL
,	NULL
serves	NULL
to	NULL
activate	NULL
a	NULL
number	NULL
of	NULL
cellular	NULL
promoters	NULL
for	NULL
growth	NULL
response	NULL
genes	NULL
(	NULL
29	NULL
,	NULL
52	NULL
,	NULL
61	NULL
)	NULL
as	NULL
well	NULL
as	NULL
the	NULL
LMP	NULL
promoters	NULL
(	NULL
15	NULL
,	NULL
62	NULL
,	NULL
66	NULL
)	NULL
and	NULL
Cp	NULL
,	NULL
an	NULL
alternative	NULL
EBNA	NULL
promoter	NULL
3	NULL
kbp	NULL
upstream	NULL
of	NULL
Wp	NULL
,	NULL
which	NULL
can	NULL
drive	NULL
expression	NULL
of	NULL
all	NULL
six	NULL
EBNA	NULL
transcripts	NULL
(	NULL
24	NULL
,	NULL
56	NULL
)	NULL
.	NULL

It	NULL
is	NULL
clear	NULL
that	NULL
activation	NULL
of	NULL
this	NULL
growth-transforming	NULL
program	NULL
of	NULL
viral	NULL
gene	NULL
expression	NULL
is	NULL
in	NULL
some	NULL
way	NULL
dependent	NULL
on	NULL
the	NULL
B-cell	NULL
environment	NULL
because	NULL
experimental	NULL
infection	NULL
of	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
epithelium	NULL
(	NULL
39	NULL
,	NULL
53	NULL
)	NULL
,	NULL
endothelium	NULL
(	NULL
25	NULL
)	NULL
,	NULL
T	NULL
cells	NULL
(	NULL
63	NULL
)	NULL
,	NULL
and	NULL
monocytes	NULL
(	NULL
49	NULL
)	NULL
,	NULL
does	NULL
not	NULL
lead	NULL
to	NULL
full	NULL
latent	NULL
protein	NULL
expression	NULL
or	NULL
autonomous	NULL
cell	NULL
growth	NULL
.	NULL

In	NULL
the	NULL
best	NULL
studied	NULL
of	NULL
these	NULL
examples	NULL
,	NULL
CR2	NULL
gene-transfected	NULL
epithelial	NULL
cells	NULL
exposed	NULL
to	NULL
the	NULL
virus	NULL
in	NULL
vitro	NULL
showed	NULL
transient	NULL
low-level	NULL
transcription	NULL
from	NULL
Wp	NULL
and	NULL
Cp	NULL
but	NULL
no	NULL
detectable	NULL
EBNAZ	NULL
or	NULL
EBNA-LP	NULL
expression	NULL
;	NULL
many	NULL
cells	NULL
became	NULL
actively	NULL
infected	NULL
,	NULL
however	NULL
,	NULL
and	NULL
selectively	NULL
expressed	NULL
the	NULL
virus	NULL
genome	NULL
maintenance	NULL
protein	NULL
EBNA1	NULL
from	NULL
an	NULL
alternative	NULL
EBNA1-specific	NULL
promoter	NULL
,	NULL
Qp	NULL
,	NULL
17	NULL
kbp	NULL
downstream	NULL
of	NULL
Wp	NULL
(	NULL
28	NULL
,	NULL
30	NULL
)	NULL
.	NULL

In	NULL
B-cell	NULL
infection	NULL
,	NULL
much	NULL
work	NULL
has	NULL
focused	NULL
on	NULL
the	NULL
mechanisms	NULL
whereby	NULL
EBNAZ	NULL
,	NULL
through	NULL
interaction	NULL
with	NULL
cellular	NULL
factors	NULL
such	NULL
as	NULL
recombination	NULL
signal	NULL
binding	NULL
protein	NULL
Jk	NULL
(	NULL
19	NULL
,	NULL
21	NULL
,	NULL
67	NULL
)	NULL
,	NULL
can	NULL
activate	NULL
the	NULL
Cp	NULL
and	NULL
LMP	NULL
promoters	NULL
and	NULL
thereby	NULL
lead	NULL
to	NULL
expression	NULL
of	NULL
the	NULL
full	NULL
range	NULL
of	NULL
virus	NULL
latent	NULL
proteins	NULL
.	NULL

What	NULL
is	NULL
less	NULL
clear	NULL
,	NULL
however	NULL
,	NULL
is	NULL
the	NULL
mechanism	NULL
whereby	NULL
Wp	NULL
is	NULL
first	NULL
activated	NULL
in	NULL
B	NULL
cells	NULL
to	NULL
initiate	NULL
the	NULL
transformation	NULL
process	NULL
.	NULL

There	NULL
have	NULL
been	NULL
a	NULL
number	NULL
of	NULL
studies	NULL
with	NULL
Wp	NULL
reporter	NULL
constructs	NULL
identifying	NULL
potential	NULL
regulatory	NULL
elements	NULL
in	NULL
the	NULL
promoter	NULL
(	NULL
23	NULL
,	NULL
47	NULL
)	NULL
,	NULL
but	NULL
apart	NULL
from	NULL
a	NULL
long-range	NULL
role	NULL
for	NULL
EBNA1	NULL
through	NULL
its	NULL
binding	NULL
to	NULL
the	NULL
orfP	NULL
region	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
5	NULL
kbp	NULL
upstream	NULL
(	NULL
42	NULL
)	NULL
,	NULL
the	NULL
factors	NULL
governing	NULL
Wp	NULL
activity	NULL
have	NULL
only	NULL
recently	NULL
begun	NULL
to	NULL
be	NULL
explored	NULL
.	NULL

Notably	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
the	NULL
low	NULL
basal	NULL
activity	NULL
of	NULL
Wp	NULL
that	NULL
is	NULL
seen	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
was	NULL
dependent	NULL
on	NULL
sequences	NULL
more	NULL
than	NULL
250	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
,	NULL
in	NULL
particular	NULL
on	NULL
a	NULL
region	NULL
called	NULL
upstream	NULL
activation	NULL
sequence	NULL
2	NULL
(	NULL
UASZ	NULL
;	NULL
-264	NULL
to	NULL
-352	NULL
)	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
which	NULL
was	NULL
primarily	NULL
dependent	NULL
on	NULL
the	NULL
ubiquitously	NULL
10458	NULL
Vor	NULL
.	NULL

74	NULL
,	NULL
2000	NULL
expressed	NULL
transcription	NULL
factor	NULL
YY1	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
much	NULL
higher	NULL
activity	NULL
shown	NULL
by	NULL
Wp	NULL
in	NULL
B-cell	NULL
lines	NULL
mapped	NULL
to	NULL
promot-er-proximal	NULL
region	NULL
UAS1	NULL
,	NULL
which	NULL
contained	NULL
at	NULL
least	NULL
three	NULL
regulatory	NULL
sites	NULL
identified	NULL
by	NULL
mutational	NULL
analysis	NULL
(	NULL
6	NULL
)	NULL
.	NULL

One	NULL
of	NULL
these	NULL
sites	NULL
bound	NULL
ubiquitously	NULL
expressed	NULL
proteins	NULL
of	NULL
the	NULL
CREB/ATF	NULL
family	NULL
(	NULL
27	NULL
)	NULL
,	NULL
but	NULL
the	NULL
identity	NULL
of	NULL
factors	NULL
binding	NULL
elsewhere	NULL
in	NULL
the	NULL
region	NULL
and	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
promoter	NULL
's	NULL
preferential	NULL
activation	NULL
in	NULL
B-cell	NULL
lines	NULL
remained	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
this	NULL
activation	NULL
requires	NULL
members	NULL
of	NULL
the	NULL
RFX	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
and	NULL
the	NULL
B-cell-specific	NULL
activator	NULL
protein	NULL
BSAP/	NULL
Pax-5	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
.	NULL

A	NULL
number	NULL
of	NULL
human	NULL
B-cell	NULL
and	NULL
non-B-cell	NULL
lines	NULL
were	NULL
used	NULL
for	NULL
the	NULL
preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
and	NULL
for	NULL
transient	NULL
transfection	NULL
assays	NULL
.	NULL

Established	NULL
B-cell	NULL
lines	NULL
were	NULL
the	NULL
EBV-negative	NULL
Burkitt	NULL
's	NULL
lymphoma-derived	NULL
cell	NULL
lines	NULL
DG75	NULL
and	NULL
Ramos	NULL
,	NULL
the	NULL
EBV-positive	NULL
Burkitt	NULL
's	NULL
lymphoma-derived	NULL
cell	NULL
line	NULL
Akata	NULL
,	NULL
and	NULL
the	NULL
EBV-transformed	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
B4	NULL
.	NULL

The	NULL
non-B	NULL
cells	NULL
included	NULL
the	NULL
T-cell	NULL
leukemic	NULL
lines	NULL
CEM	NULL
and	NULL
Jurkat	NULL
,	NULL
the	NULL
procrythroleukemic	NULL
line	NULL
K562	NULL
,	NULL
and	NULL
the	NULL
simian	NULL
virus	NULL
40-transformed	NULL
epidermal	NULL
keratinocyte	NULL
line	NULL
Rhek	NULL
.	NULL

All	NULL
cells	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
Rhek	NULL
were	NULL
maintained	NULL
as	NULL
suspension	NULL
cultures	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
selected	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
and	NULL
100	NULL
mg	NULL
of	NULL
gentamicin	NULL
per	NULL
liter	NULL
.	NULL

Rhek	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
Joklik	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
8	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
and	NULL
0.4	NULL
pg	NULL
of	NULL
hydrocortisone	NULL
per	NULL
ml	NULL
.	NULL

Plasmid	NULL
constructs	NULL
.	NULL

The	NULL
Wp440/GL2	NULL
reporter	NULL
plasmid	NULL
,	NULL
in	NULL
which	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
Wp	NULL
sequence	NULL
positions	NULL
-440	NULL
to	NULL
+175	NULL
(	NULL
relative	NULL
to	NULL
the	NULL
Wp	NULL
RNA	NULL
start	NULL
site	NULL
)	NULL
,	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
6	NULL
)	NULL
.	NULL

The	NULL
site	NULL
B	NULL
,	NULL
site	NULL
C	NULL
,	NULL
and	NULL
site	NULL
D	NULL
mutant	NULL
reporter	NULL
constructs	NULL
were	NULL
made	NULL
using	NULL
appropriate	NULL
oligonucleotides	NULL
and	NULL
the	NULL
Sculptor	NULL
mutagenesis	NULL
system	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
)	NULL
.	NULL

The	NULL
BSAP	NULL
expression	NULL
vector	NULL
containing	NULL
the	NULL
human	NULL
BSAP	NULL
cDNA	NULL
cloned	NULL
into	NULL
pSG5	NULL
(	NULL
44	NULL
)	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Andreas	NULL
Reimold	NULL
(	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

.	NULL

Bandshift	NULL
assays	NULL
.	NULL

The	NULL
preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
and	NULL
the	NULL
in	NULL
vitro	NULL
binding	NULL
assays	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
6	NULL
)	NULL
,	NULL
binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
either	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
)	NULL
or	NULL
sheared	NULL
herring	NULL
sperm	NULL
DNA	NULL
(	NULL
Sigma	NULL
)	NULL
to	NULL
reduce	NULL
complex	NULL
formation	NULL
due	NULL
to	NULL
nonspecific	NULL
DNA	NULL
binding	NULL
proteins	NULL
.	NULL

In	NULL
the	NULL
initial	NULL
bandshift	NULL
assays	NULL
,	NULL
long	NULL
probes	NULL
carrying	NULL
Wp	NULL
sequence	NULL
positions	NULL
-352	NULL
to	NULL
-264	NULL
,	NULL
-264	NULL
to	NULL
-135	NULL
,	NULL
and	NULL
-135	NULL
to	NULL
-70	NULL
were	NULL
generated	NULL
by	NULL
digestion	NULL
of	NULL
Wp440/GL2	NULL
Basic	NULL
with	NULL
Secl/Avril	NULL
,	NULL
Avrll/Apel	NULL
,	NULL
and	NULL
Apal/MunI	NULL
,	NULL
respectively	NULL
.	NULL

Two	NULL
additional	NULL
overlapping	NULL
probes	NULL
,	NULL
-316/-135	NULL
and	NULL
-170/-70	NULL
,	NULL
were	NULL
generated	NULL
by	NULL
Sacl/Apal	NULL
digestion	NULL
of	NULL
a	NULL
truncated	NULL
Wp	NULL
reporter	NULL
plasmid	NULL
Wp316/GL2	NULL
Basic	NULL
produced	NULL
as	NULL
one	NULL
of	NULL
a	NULL
series	NULL
of	NULL
promoter	NULL
truncations	NULL
in	NULL
earlier	NULL
work	NULL
(	NULL
6	NULL
)	NULL
and	NULL
by	NULL
Ncol/Mun	NULL
!	NULL

digestion	NULL
of	NULL
a	NULL
Wp440	NULL
derivative	NULL
in	NULL
which	NULL
an	NULL
NcoI	NULL
site	NULL
had	NULL
been	NULL
introduced	NULL
at	NULL
-173	NULL
to	NULL
-168	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
appropriate	NULL
fragments	NULL
were	NULL
then	NULL
dephosphorylated	NULL
using	NULL
alkaline	NULL
phosphatase	NULL
and	NULL
gel	NULL
purified	NULL
before	NULL
labeling	NULL
with	NULL
[	NULL
y-	NULL
>	NULL
°P	NULL
]	NULL
JATP	NULL
and	NULL
polynucleotide	NULL
kinase	NULL
.	NULL

The	NULL
short	NULL
double-stranded	NULL
oligonucleotide	NULL
competitors	NULL
(	NULL
Alta	NULL
Biosciences	NULL
,	NULL
University	NULL
of	NULL
Birmingham	NULL
)	NULL
used	NULL
for	NULL
Fig	NULL
.	NULL

2	NULL
were	NULL
MIF-1	NULL
(	NULL
GATCTAGAGTAGTTATGGTA	NULL
ACTGGG	NULL
)	NULL
,	NULL
MIF-1	NULL
m	NULL
(	NULL
GATCTAGAGTAGTTATGATTACTGGG	NULL
)	NULL
,	NULL
HBV	NULL
enh-I	NULL
(	NULL
GATCCGTTGCTCGGCAACGGCCTA	NULL
)	NULL
,	NULL
HBV	NULL
enh-I	NULL
m	NULL
(	NULL
GATCCCAA	NULL
CCTCGGCAACGGCCTA	NULL
)	NULL
,	NULL
and	NULL
HLA	NULL
DRA	NULL
X	NULL
(	NULL
GATCCCCTTCCCCTAGCA	NULL
ACAGATGA	NULL
)	NULL
(	NULL
mutations	NULL
are	NULL
underlined	NULL
)	NULL
;	NULL
designations	NULL
are	NULL
explained	NULL
in	NULL
Re-sults	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
minimal	NULL
sequence	NULL
required	NULL
for	NULL
factor	NULL
binding	NULL
to	NULL
site	NULL
D	NULL
within	NULL
the	NULL
-264/-135	NULL
probe	NULL
,	NULL
a	NULL
number	NULL
of	NULL
truncated	NULL
double-stranded	NULL
oligonucleotide	NULL
competitors	NULL
carrying	NULL
Wp	NULL
sequences	NULL
-254/-215	NULL
,	NULL
-254/-220	NULL
,	NULL
-242/	NULL
-215	NULL
,	NULL
-242/-220	NULL
,	NULL
-237/-215	NULL
,	NULL
and	NULL
-232/-215	NULL
were	NULL
synthesized	NULL
.	NULL

Competitor	NULL
oligonucleotides	NULL
and/or	NULL
probes	NULL
containing	NULL
the	NULL
wild-type	NULL
and	NULL
mutant	NULL
YY1	NULL
sites	NULL
(	NULL
Wp	NULL
-308/-279	NULL
and	NULL
mut	NULL
YY1	NULL
)	NULL
,	NULL
the	NULL
CREB	NULL
site	NULL
(	NULL
Wp	NULL
-102/-77	NULL
)	NULL
,	NULL
and	NULL
sites	NULL
B	NULL
(	NULL
Wp	NULL
-115/-86	NULL
)	NULL
and	NULL
C	NULL
(	NULL
Wp	NULL
-140/-99	NULL
)	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
6	NULL
)	NULL
;	NULL
in	NULL
some	NULL
cases	NULL
the	NULL
site	NULL
C	NULL
competitor	NULL
sequence	NULL
and	NULL
its	NULL
mutant	NULL
derivatives	NULL
were	NULL
shortened	NULL
to	NULL
nucleotides	NULL
-125	NULL
to	NULL
-99	NULL
.	NULL

Competitor	NULL
oligonucleotides	NULL
(	NULL
1,000-fold	NULL
excess	NULL
unless	NULL
stated	NULL
otherwise	NULL
)	NULL
were	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
radiolabeled	NULL
probe	NULL
.	NULL

The	NULL
following	NULL
antibodies	NULL
,	NULL
purchased	NULL
as	NULL
Tran-sCruz	NULL
Gel	NULL
Supershift	NULL
reagents	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
were	NULL
also	NULL
included	NULL
in	NULL
the	NULL
relevant	NULL
binding	NULL
reactions	NULL
:	NULL
a	NULL
rabbit	NULL
polyclonal	NULL
antibody	NULL
against	NULL
YY1	NULL
(	NULL
C-20	NULL
)	NULL
,	NULL
a	NULL
mouse	NULL
monoclonal	NULL
antibody	NULL
against	NULL
CREB	NULL
proteins	NULL
(	NULL
25C	NULL
10G	NULL
)	NULL
,	NULL
a	NULL
rabbit	NULL
polyclonal	NULL
antibody	NULL
against	NULL
Octl	NULL
(	NULL
C-21	NULL
)	NULL
,	NULL
and	NULL
a	NULL
goat	NULL
polyclonal	NULL
antibody	NULL
against	NULL
BSAP	NULL
(	NULL
C-20	NULL
)	NULL
.	NULL

Antisera	NULL
against	NULL
RFX1	NULL
,	NULL
RFX3	NULL
,	NULL
and	NULL
RFX5	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Walter	NULL
Reith	NULL
(	NULL
University	NULL
of	NULL
Geneva	NULL
,	NULL
Geneva	NULL
,	NULL
Switzerland	NULL
)	NULL
,	NULL
and	NULL
the	NULL
MIBP1	NULL
antiserum	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Maria	NULL
Zajac-Kaye	NULL
(	NULL
Naval	NULL
Oncology	NULL
Center	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

.	NULL

In	NULL
vitro-translated	NULL
(	NULL
IVT	NULL
)	NULL
YY1	NULL
and	NULL
BSAP	NULL
were	NULL
generated	NULL
using	NULL
the	NULL
T7	NULL
TNT	NULL
coupled	NULL
reticulocyte	NULL
lysate	NULL
system	NULL
(	NULL
Promega	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Transient	NULL
transfection	NULL
and	NULL
reporter	NULL
assays	NULL
.	NULL

Cell	NULL
cultures	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
8	NULL
ug	NULL
of	NULL
luciferase	NULL
reporter	NULL
containing	NULL
the	NULL
relevant	NULL
Wp	NULL
sequences	NULL
and	NULL
2	NULL
g	NULL
of	NULL
a	NULL
constitutively	NULL
expressed	NULL
-galactosidase	NULL
reporter	NULL
(	NULL
CMV-	NULL
EBV	NULL
PROMOTER	NULL
REGULATION	NULL
BY	NULL
RFX	NULL
AND	NULL
BSAP	NULL
-	NULL
10459	NULL
Bgal	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Wp	NULL
reporter	NULL
activities	NULL
were	NULL
measured	NULL
by	NULL
quantifying	NULL
luciferase	NULL
expression	NULL
in	NULL
whole-cell	NULL
extracts	NULL
at	NULL
16	NULL
to	NULL
24	NULL
h	NULL
posttrans-fection	NULL
;	NULL
the	NULL
luciferase	NULL
activity	NULL
in	NULL
each	NULL
sample	NULL
was	NULL
then	NULL
normalized	NULL
for	NULL
variations	NULL
in	NULL
transfection	NULL
efficiency	NULL
by	NULL
measuring	NULL
the	NULL
level	NULL
of	NULL
B-galactosidase	NULL
expression	NULL
from	NULL
the	NULL
cotransfected	NULL
CMV-Bgal	NULL
plasmid	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
the	NULL
BSAP	NULL
transactivation	NULL
experiments	NULL
,	NULL
2	NULL
pg	NULL
of	NULL
BSAP/pSGS	NULL
or	NULL
2	NULL
ug	NULL
of	NULL
empty	NULL
pSGS	NULL
vector	NULL
was	NULL
included	NULL
with	NULL
the	NULL
appropriate	NULL
luciferase	NULL
reporter	NULL
constructs	NULL
and	NULL
CMV-Bgal	NULL
as	NULL
above	NULL
.	NULL

RESULTS	NULL
Binding	NULL
of	NULL
lineage-independent	NULL
and	NULL
B-cell-specific	NULL
factors	NULL
to	NULL
Wp	NULL
sequences	NULL
.	NULL

Figure	NULL
1a	NULL
shows	NULL
a	NULL
schematic	NULL
representation	NULL
of	NULL
Wp	NULL
in	NULL
its	NULL
genomic	NULL
context	NULL
,	NULL
downstream	NULL
of	NULL
oriP	NULL
and	NULL
Cp	NULL
,	NULL
and	NULL
identifies	NULL
the	NULL
main	NULL
lineage-independent	NULL
regulatory	NULL
region	NULL
UASZ2	NULL
with	NULL
its	NULL
constituent	NULL
YY1	NULL
site	NULL
and	NULL
the	NULL
B-cell-specific	NULL
region	NULL
UAS1	NULL
with	NULL
its	NULL
constituent	NULL
CREB/ATF	NULL
site	NULL
.	NULL

The	NULL
additional	NULL
sites	NULL
(	NULL
B	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
)	NULL
within	NULL
UAS1	NULL
were	NULL
either	NULL
known	NULL
from	NULL
earlier	NULL
work	NULL
(	NULL
6	NULL
)	NULL
or	NULL
identified	NULL
in	NULL
the	NULL
present	NULL
study	NULL
.	NULL

Since	NULL
our	NULL
previous	NULL
analysis	NULL
of	NULL
factor	NULL
binding	NULL
to	NULL
Wp	NULL
had	NULL
used	NULL
short	NULL
oligonucleotide	NULL
probes	NULL
representing	NULL
only	NULL
a	NULL
few	NULL
selected	NULL
sequences	NULL
within	NULL
the	NULL
promoter	NULL
,	NULL
we	NULL
first	NULL
carried	NULL
out	NULL
a	NULL
more	NULL
systematic	NULL
screening	NULL
using	NULL
a	NULL
series	NULL
of	NULL
longer	NULL
radiolabeled	NULL
probes	NULL
designed	NULL
to	NULL
cover	NULL
the	NULL
entire	NULL
-352	NULL
to	NULL
-70	NULL
region	NULL
.	NULL

Focusing	NULL
first	NULL
on	NULL
UAS2	NULL
,	NULL
Fig	NULL
.	NULL

1b	NULL
shows	NULL
the	NULL
protein-DNA	NULL
complexes	NULL
formed	NULL
when	NULL
the	NULL
-352/-264	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
B-cell	NULL
lines	NULL
(	NULL
Akata	NULL
,	NULL
Ramos	NULL
,	NULL
DG75	NULL
,	NULL
and	NULL
1B4	NULL
)	NULL
or	NULL
from	NULL
non-B-cell	NULL
lines	NULL
of	NULL
epithelial	NULL
(	NULL
Rhek	NULL
)	NULL
,	NULL
T-cell	NULL
(	NULL
CEM	NULL
and	NULL
Jurkat	NULL
)	NULL
,	NULL
and	NULL
erythroleukemic	NULL
cell	NULL
(	NULL
K562	NULL
)	NULL
origin	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
,	NULL
we	NULL
detected	NULL
the	NULL
same	NULL
two	NULL
complexes	NULL
,	NULL
implying	NULL
that	NULL
this	NULL
lincage-independent	NULL
region	NULL
of	NULL
Wp	NULL
interacts	NULL
only	NULL
with	NULL
ubiquitously	NULL
expressed	NULL
factors	NULL
.	NULL

The	NULL
data	NULL
in	NULL
Fig	NULL
.	NULL

1b	NULL
strengthen	NULL
our	NULL
earlier	NULL
conclusion	NULL
that	NULL
the	NULL
cellular	NULL
factor	NULL
YY1	NULL
is	NULL
the	NULL
major	NULL
determinant	NULL
of	NULL
UAS2	NULL
activity	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
formation	NULL
of	NULL
both	NULL
complexes	NULL
could	NULL
be	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
short	NULL
oligonucleotide	NULL
competitor	NULL
representing	NULL
the	NULL
minimal	NULL
YY1	NULL
binding	NULL
sequence	NULL
from	NULL
-308	NULL
to	NULL
-279	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
but	NULL
not	NULL
by	NULL
mut	NULL
YY1	NULL
,	NULL
a	NULL
sequence	NULL
that	NULL
had	NULL
lost	NULL
YY1	NULL
binding	NULL
activity	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
;	NULL
furthermore	NULL
,	NULL
both	NULL
complexes	NULL
were	NULL
supershifted	NULL
by	NULL
a	NULL
YY1-specific	NULL
polyclonal	NULL
antibody	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Since	NULL
incubation	NULL
of	NULL
the	NULL
probe	NULL
with	NULL
IVT	NULL
YY1	NULL
reproduced	NULL
only	NULL
the	NULL
faster-migrating	NULL
of	NULL
the	NULL
two	NULL
complexes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
we	NULL
infer	NULL
that	NULL
this	NULL
faster-migrating	NULL
complex	NULL
contains	NULL
YY1	NULL
alone	NULL
whereas	NULL
the	NULL
second	NULL
complex	NULL
contains	NULL
YY1	NULL
and	NULL
an	NULL
additional	NULL
cellular	NULL
factor	NULL
.	NULL

We	NULL
then	NULL
monitored	NULL
complex	NULL
formation	NULL
using	NULL
a	NULL
second	NULL
large	NULL
probe	NULL
,	NULL
Wp	NULL
-135/-70	NULL
,	NULL
spanning	NULL
a	NULL
region	NULL
previously	NULL
shown	NULL
to	NULL
encompass	NULL
a	NULL
CREB	NULL
binding	NULL
site	NULL
and	NULL
two	NULL
adjacent	NULL
sites	NULL
,	NULL
B	NULL
and	NULL
C.	NULL
Note	NULL
that	NULL
here	NULL
,	NULL
as	NULL
in	NULL
all	NULL
experiments	NULL
with	NULL
long	NULL
probes	NULL
,	NULL
we	NULL
screened	NULL
for	NULL
factor	NULL
binding	NULL
under	NULL
two	NULL
different	NULL
reaction	NULL
conditions	NULL
since	NULL
we	NULL
had	NULL
previously	NULL
noted	NULL
that	NULL
complex	NULL
formation	NULL
at	NULL
certain	NULL
sites	NULL
in	NULL
Wp	NULL
was	NULL
differentially	NULL
affected	NULL
by	NULL
the	NULL
choice	NULL
of	NULL
nonspecific	NULL
DNA	NULL
competitor	NULL
.	NULL

Under	NULL
the	NULL
first	NULL
set	NULL
of	NULL
conditions	NULL
(	NULL
Fig	NULL
.	NULL

1e	NULL
)	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
the	NULL
only	NULL
detectable	NULL
complexes	NULL
could	NULL
be	NULL
specifically	NULL
competed	NULL
out	NULL
using	NULL
a	NULL
small	NULL
oligonucleotide	NULL
representing	NULL
the	NULL
minimal	NULL
CREB	NULL
site	NULL
sequence	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
but	NULL
not	NULL
by	NULL
competitors	NULL
representing	NULL
site	NULL
B	NULL
or	NULL
C	NULL
(	NULL
lane	NULL
9	NULL
or	NULL
10	NULL
)	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
these	NULL
ubiquitously	NULL
expressed	NULL
proteins	NULL
as	NULL
members	NULL
of	NULL
the	NULL
CREB/ATF	NULL
family	NULL
was	NULL
confirmed	NULL
by	NULL
supershift	NULL
experiments	NULL
using	NULL
a	NULL
CREB/ATF	NULL
antibody	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Parallel	NULL
experiments	NULL
in	NULL
which	NULL
the	NULL
Wp	NULL
-135/-70	NULL
probe	NULL
was	NULL
incubated	NULL
under	NULL
alternative	NULL
binding	NULL
conditions	NULL
(	NULL
Fig	NULL
.	NULL

1d	NULL
)	NULL
revealed	NULL
a	NULL
number	NULL
of	NULL
slow-migrating	NULL
complexes	NULL
which	NULL
were	NULL
detected	NULL
using	NULL
nuclear	NULL
extracts	NULL
of	NULL
both	NULL
B-cell	NULL
and	NULL
non-B-cell	NULL
lines	NULL
;	NULL
these	NULL
complexes	NULL
appeared	NULL
identical	NULL
to	NULL
those	NULL
previously	NULL
obtained	NULL
using	NULL
a	NULL
short	NULL
site	NULL
C	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
6	NULL
)	NULL
,	NULL
since	NULL
their	NULL
formation	NULL
was	NULL
specifically	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
site	NULL
C	NULL
competitor	NULL
10460	NULL
TIERNEY	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
VirRou	NULL
.	NULL

a	NULL
orxP	NULL
Cp	NULL
Wpr	NULL
>	NULL
/\	NULL
UASZ	NULL
lineage-independent	NULL
i	NULL
yo	NULL
)	NULL
___	NULL
fsiepl	NULL
-264/-	NULL
135	NULL
-352/-264	NULL
wz	NULL
/_	NULL
UAS1	NULL
,	NULL
B	NULL
cell-specific	NULL
Isite	NULL
Clsile	NULL
BICREEI	NULL
I	NULL
-	NULL
I	NULL
35/-70	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
1	NULL
2	NULL
3	NULL
4	NULL
1	NULL
2	NULL
3	NULL
4	NULL
S	NULL
60	NULL
708	NULL
%	NULL
9	NULL
10	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Binding	NULL
of	NULL
lineage-dependent	NULL
and	NULL
lineage-independent	NULL
factors	NULL
to	NULL
Wp	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Schematic	NULL
illustration	NULL
of	NULL
the	NULL
region	NULL
of	NULL
the	NULL
EBV	NULL
genome	NULL
containing	NULL
the	NULL
origin	NULL
of	NULL
plasmid	NULL
replication	NULL
orP	NULL
and	NULL
the	NULL
viral	NULL
latent	NULL
cycle	NULL
promoters	NULL
Cp	NULL
and	NULL
Wp	NULL
.	NULL

Below	NULL
this	NULL
is	NULL
a	NULL
detailed	NULL
map	NULL
of	NULL
Wp	NULL
showing	NULL
its	NULL
main	NULL
lineage-independent	NULL
(	NULL
UAS2	NULL
)	NULL
and	NULL
B-cell-specific	NULL
(	NULL
UAS1	NULL
)	NULL
regulatory	NULL
elements	NULL
and	NULL
their	NULL
constituent	NULL
binding	NULL
sites	NULL
for	NULL
either	NULL
known	NULL
(	NULL
YY1	NULL
and	NULL
CREB	NULL
)	NULL
or	NULL
unknown	NULL
(	NULL
sites	NULL
B	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
)	NULL
cellular	NULL
factors	NULL
.	NULL

Also	NULL
shown	NULL
are	NULL
horizontal	NULL
bars	NULL
representing	NULL
the	NULL
three	NULL
principal	NULL
Wp	NULL
restriction	NULL
fragments	NULL
used	NULL
as	NULL
bandshift	NULL
probes	NULL
to	NULL
screen	NULL
for	NULL
factor	NULL
binding	NULL
.	NULL

(	NULL
b	NULL
to	NULL
e	NULL
)	NULL
Patterns	NULL
of	NULL
protein-DNA	NULL
complexes	NULL
obtained	NULL
by	NULL
incubating	NULL
these	NULL
Wp	NULL
probes	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
the	NULL
indicated	NULL
B-	NULL
and	NULL
non-B-cell	NULL
lines	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Complexes	NULL
obtained	NULL
using	NULL
the	NULL
Wp	NULL
-352/-264	NULL
probe	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

Lanes	NULL
1	NULL
to	NULL
8	NULL
,	NULL
probe	NULL
plus	NULL
the	NULL
indicated	NULL
nuclear	NULL
extract	NULL
;	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
,	NULL
probe	NULL
plus	NULL
Akata	NULL
nuclear	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
oligonucleotide	NULL
competitor	NULL
(	NULL
comp	NULL
)	NULL
containing	NULL
either	NULL
the	NULL
minimal	NULL
YY1	NULL
binding	NULL
sequence	NULL
within	NULL
UAS2	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
or	NULL
the	NULL
variant	NULL
sequence	NULL
mut	NULL
YY1	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Complexes	NULL
obtained	NULL
using	NULL
the	NULL
Wp	NULL
-264/-135	NULL
probe	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
plus	NULL
the	NULL
indicated	NULL
nuclear	NULL
extract	NULL
.	NULL

Note	NULL
that	NULL
the	NULL
unusually	NULL
strong	NULL
intensity	NULL
of	NULL
the	NULL
site	NULL
D	NULL
complex	NULL
in	NULL
lane	NULL
1	NULL
is	NULL
due	NULL
to	NULL
differences	NULL
in	NULL
protein	NULL
loading	NULL
rather	NULL
than	NULL
a	NULL
difference	NULL
in	NULL
expression	NULL
of	NULL
the	NULL
site	NULL
D	NULL
binding	NULL
factor	NULL
.	NULL

(	NULL
d	NULL
)	NULL
Complexes	NULL
obtained	NULL
using	NULL
the	NULL
Wp	NULL
-135/-70	NULL
probe	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

Lanes	NULL
1	NULL
to	NULL
7	NULL
,	NULL
probe	NULL
plus	NULL
the	NULL
indicated	NULL
nuclear	NULL
extract	NULL
;	NULL
lanes	NULL
8	NULL
to	NULL
10	NULL
,	NULL
probe	NULL
plus	NULL
Akata	NULL
nuclear	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
minimal	NULL
CREB	NULL
binding	NULL
sequence	NULL
as	NULL
competitor	NULL
,	NULL
a	NULL
site	NULL
B	NULL
competitor	NULL
,	NULL
and	NULL
a	NULL
site	NULL
C	NULL
competitor	NULL
,	NULL
respectively	NULL
.	NULL

(	NULL
e	NULL
)	NULL
Complexes	NULL
obtained	NULL
using	NULL
the	NULL
same	NULL
Wp	NULL
-135/-70	NULL
probe	NULL
but	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
herring	NULL
sperm	NULL
DNA	NULL
.	NULL

Lanes	NULL
are	NULL
as	NULL
in	NULL
panel	NULL
d.	NULL
but	NULL
not	NULL
site	NULL
B	NULL
or	NULL
CREB	NULL
site	NULL
sequences	NULL
.	NULL

More	NULL
importantly	NULL
,	NULL
a	NULL
faster-migrating	NULL
complex	NULL
was	NULL
detected	NULL
exclusively	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
B-cell	NULL
extracts	NULL
.	NULL

We	NULL
found	NULL
that	NULL
this	NULL
complex	NULL
reflected	NULL
factor	NULL
binding	NULL
to	NULL
site	NULL
B	NULL
within	NULL
the	NULL
large	NULL
Wp	NULL
-135/-70	NULL
probe	NULL
,	NULL
since	NULL
a	NULL
short	NULL
oligonucleotide	NULL
competitor	NULL
representing	NULL
site	NULL
B	NULL
specifically	NULL
blocked	NULL
the	NULL
interaction	NULL
.	NULL

A	NULL
further	NULL
set	NULL
of	NULL
bandshift	NULL
assays	NULL
used	NULL
a	NULL
long	NULL
probe	NULL
,	NULL
Wp	NULL
-264/-135	NULL
(	NULL
Fig	NULL
.	NULL

1c	NULL
)	NULL
,	NULL
spanning	NULL
a	NULL
region	NULL
not	NULL
analyzed	NULL
in	NULL
detail	NULL
in	NULL
earlier	NULL
work	NULL
.	NULL

Interestingly	NULL
,	NULL
this	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
single	NULL
protein-DNA	NULL
complex	NULL
which	NULL
,	NULL
like	NULL
that	NULL
at	NULL
site	NULL
B	NULL
,	NULL
was	NULL
observed	NULL
only	NULL
with	NULL
B-cell	NULL
extracts	NULL
.	NULL

We	NULL
therefore	NULL
took	NULL
this	NULL
as	NULL
evidence	NULL
for	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
new	NULL
binding	NULL
site	NULL
,	NULL
site	NULL
D	NULL
,	NULL
within	NULL
the	NULL
-264	NULL
to	NULL
-135	NULL
region	NULL
;	NULL
the	NULL
precise	NULL
location	NULL
of	NULL
site	NULL
D	NULL
was	NULL
determined	NULL
subsequently	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

To	NULL
eliminate	NULL
the	NULL
possibility	NULL
of	NULL
additional	NULL
binding	NULL
sites	NULL
located	NULL
in	NULL
the	NULL
junction	NULL
regions	NULL
between	NULL
the	NULL
long	NULL
probes	NULL
used	NULL
above	NULL
,	NULL
we	NULL
also	NULL
generated	NULL
two	NULL
further	NULL
fragments	NULL
carrying	NULL
Wp	NULL
sequences	NULL
which	NULL
spanned	NULL
these	NULL
junctions	NULL
.	NULL

However	NULL
,	NULL
bandshift	NULL
assays	NULL
using	NULL
these	NULL
two	NULL
new	NULL
probes	NULL
,	NULL
Wp	NULL
-316/-135	NULL
and	NULL
Wp	NULL
-170/-70	NULL
,	NULL
did	NULL
not	NULL
detect	NULL
any	NULL
additional	NULL
complexes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
while	NULL
the	NULL
results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1b	NULL
to	NULL
e	NULL
were	NULL
obtained	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
established	NULL
B-cell	NULL
lines	NULL
,	NULL
we	NULL
also	NULL
observed	NULL
the	NULL
same	NULL
DNA	NULL
binding	NULL
factors	NULL
in	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
freshly	NULL
isolated	NULL
primary	NULL
B	NULL
lymphocytes	NULL
(	NULL
the	NULL
natural	NULL
target	NULL
cells	NULL
for	NULL
EBV	NULL
infection	NULL
)	NULL
,	NULL
and	NULL
levels	NULL
of	NULL
these	NULL
factors	NULL
were	NULL
not	NULL
altered	NULL
following	NULL
virus	NULL
binding	NULL
and	NULL
in	NULL
vitro	NULL
infection	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
YY1	NULL
,	NULL
CREB/ATF	NULL
,	NULL
and	NULL
the	NULL
unidentified	NULL
factors	NULL
binding	NULL
sites	NULL
B	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
represent	NULL
the	NULL
full	NULL
complement	NULL
of	NULL
B-cell	NULL
transcription	NULL
factors	NULL
associated	NULL
with	NULL
Wp	NULL
sequence	NULL
from	NULL
-352	NULL
to	NULL
-70	NULL
.	NULL

Identification	NULL
of	NULL
RFX	NULL
proteins	NULL
binding	NULL
to	NULL
site	NULL
C.	NULL
Focusing	NULL
first	NULL
on	NULL
site	NULL
C	NULL
(	NULL
-140	NULL
to	NULL
-99	NULL
)	NULL
,	NULL
we	NULL
searched	NULL
the	NULL
TRANSFAC	NULL
database	NULL
to	NULL
identify	NULL
potential	NULL
cellular	NULL
factors	NULL
that	NULL
might	NULL
bind	NULL
to	NULL
this	NULL
sequence	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
this	NULL
revealed	NULL
a	NULL
significant	NULL
homology	NULL
between	NULL
nucleotides	NULL
-122	NULL
to	NULL
-110	NULL
and	NULL
the	NULL
consensus	NULL
binding	NULL
motif	NULL
for	NULL
the	NULL
RFX	NULL
family	NULL
of	NULL
transcriptional	NULL
regulators	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Of	NULL
these	NULL
,	NULL
RFX1	NULL
,	NULL
RFX2	NULL
,	NULL
and	NULL
RFX3	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
viral	NULL
and	NULL
cellular	NULL
genes	NULL
and	NULL
shown	NULL
to	NULL
bind	NULL
target	NULL
sites	NULL
as	NULL
both	NULL
homodimers	NULL
and	NULL
heterodimers	NULL
(	NULL
22	NULL
,	NULL
31	NULL
,	NULL
45	NULL
,	NULL
46	NULL
,	NULL
48	NULL
,	NULL
50	NULL
,	NULL
51	NULL
)	NULL
,	NULL
while	NULL
RFXS	NULL
specifically	NULL
associates	NULL
with	NULL
the	NULL
promoters	NULL
of	NULL
HLA	NULL
class	NULL
II	NULL
genes	NULL
as	NULL
a	NULL
complex	NULL
with	NULL
two	NULL
other	NULL
proteins	NULL
,	NULL
RFX-AP	NULL
and	NULL
RFX-ANK/	NULL
RFX-B	NULL
(	NULL
12	NULL
,	NULL
34	NULL
,	NULL
37	NULL
,	NULL
55	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
another	NULL
cellular	NULL
factor	NULL
,	NULL
MIBP1	NULL
(	NULL
myc	NULL
intron	NULL
binding	NULL
factor	NULL
1	NULL
)	NULL
,	NULL
first	NULL
identified	NULL
as	NULL
a	NULL
regulator	NULL
of	NULL
c-myc	NULL
gene	NULL
expression	NULL
(	NULL
65	NULL
)	NULL
,	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
RFX-dependent	NULL
promoters	NULL
(	NULL
45	NULL
)	NULL
and	NULL
can	NULL
form	NULL
heterodimers	NULL
with	NULL
at	NULL
least	NULL
one	NULL
member	NULL
of	NULL
the	NULL
RFX	NULL
family	NULL
,	NULL
RFX1	NULL
(	NULL
7	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
if	NULL
site	NULL
C	NULL
can	NULL
interact	NULL
with	NULL
these	NULL
RFX	NULL
factors	NULL
,	NULL
a	NULL
radiolabeled	NULL
site	NULL
C	NULL
oligonucleotide	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
Vor	NULL
.	NULL

74	NULL
,	NULL
2000	NULL
A	NULL
|	NULL
he	NULL
RFX	NULL
A	NULL
consensus	NULL
(	NULL
6	NULL
,	NULL
AAC	NULL
EBV	NULL
Site	NULL
C	NULL
GTTGC-TAGGCCAC	NULL
EBV	NULL
Site	NULL
C	NULL
ml	NULL
GTACC-TAGGCCAC	NULL
HBV	NULL
enh-I	NULL
GTTGC-TCGGCAAC	NULL
HBV	NULL
enh-I	NULL
m	NULL
CAACC-TCGGCAAC	NULL
MIF-1	NULL
GTTAT	NULL
--	NULL
-GGTAAC	NULL
MIF-1	NULL
m	NULL
GTTAT	NULL
--	NULL
-GATTAC	NULL
HLA	NULL
DRA	NULL
X	NULL
CTTCCCCTAGCAAC	NULL
B	NULL
DG75	NULL
+	NULL
competitor	NULL
Jurkat	NULL
+	NULL
competitor	NULL
I	NULL
U	NULL
I	NULL
I	NULL
o	NULL
E4	NULL
,	NULL
6000	NULL
%	NULL
ece	NULL
_	NULL
igffl	NULL
.	NULL

:	NULL
f	NULL
§	NULL
2	NULL
a	NULL
50g	NULL
g	NULL
>	NULL
>	NULL
Lok	NULL
<	NULL
-	NULL
¥	NULL
u	NULL
Q	NULL
t	NULL
pod	NULL
Io	NULL
20	NULL
03	NULL
40	NULL
50	NULL
60	NULL
70	NULL
8	NULL
Io	NULL
20	NULL
30	NULL
40	NULL
50	NULL
6007	NULL
8	NULL
Io	NULL
2	NULL
30	NULL
40	NULL
5	NULL
06	NULL
Io	NULL
20030	NULL
40	NULL
5	NULL
6	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

EBV	NULL
Wp	NULL
site	NULL
C	NULL
binds	NULL
factors	NULL
belonging	NULL
to	NULL
the	NULL
RFX/MIBP1	NULL
family	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Sequence	NULL
comparison	NULL
of	NULL
Wp	NULL
nucleotides	NULL
-122	NULL
to	NULL
-110	NULL
within	NULL
site	NULL
C	NULL
and	NULL
known	NULL
RFX/MIBP1	NULL
binding	NULL
sites	NULL
.	NULL

The	NULL
top	NULL
line	NULL
shows	NULL
a	NULL
published	NULL
consensus	NULL
RFX1	NULL
binding	NULL
site	NULL
(	NULL
14	NULL
)	NULL
as	NULL
an	NULL
imperfect	NULL
inverted	NULL
repeat	NULL
comprising	NULL
two	NULL
half-sites	NULL
(	NULL
arrowed	NULL
)	NULL
separated	NULL
by	NULL
a	NULL
variable	NULL
spacer	NULL
region	NULL
.	NULL

Shown	NULL
below	NULL
are	NULL
the	NULL
relevant	NULL
sequences	NULL
from	NULL
the	NULL
wild-type	NULL
Wp	NULL
site	NULL
C	NULL
and	NULL
from	NULL
a	NULL
mutant	NULL
derivative	NULL
(	NULL
site	NULL
C	NULL
m1	NULL
)	NULL
previously	NULL
shown	NULL
to	NULL
have	NULL
lost	NULL
factor	NULL
binding	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Also	NULL
shown	NULL
are	NULL
the	NULL
sequences	NULL
of	NULL
several	NULL
published	NULL
RFX/MIBP1	NULL
binding	NULL
sites	NULL
(	NULL
HBV	NULL
enh	NULL
I	NULL
,	NULL
MIF-1	NULL
,	NULL
and	NULL
HLA	NULL
DRA	NULL
X	NULL
[	NULL
45	NULL
]	NULL
)	NULL
which	NULL
were	NULL
used	NULL
as	NULL
competitors	NULL
in	NULL
bandshift	NULL
assays	NULL
.	NULL

HBV	NULL
enhl	NULL
m	NULL
and	NULL
MIF-1	NULL
m	NULL
,	NULL
mutant	NULL
sequences	NULL
previously	NULL
shown	NULL
to	NULL
no	NULL
longer	NULL
bind	NULL
RFX/	NULL
MIBP1	NULL
(	NULL
45	NULL
)	NULL
,	NULL
were	NULL
included	NULL
as	NULL
controls	NULL
;	NULL
nucleotide	NULL
substitutions	NULL
are	NULL
shaded	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Protein-DNA	NULL
complexes	NULL
obtained	NULL
by	NULL
incubating	NULL
a	NULL
site	NULL
C	NULL
probe	NULL
with	NULL
DG75	NULL
or	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
probe	NULL
plus	NULL
nuclear	NULL
extract	NULL
alone	NULL
;	NULL
lanes	NULL
2	NULL
to	NULL
8	NULL
,	NULL
probe	NULL
plus	NULL
nuclear	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
competitor	NULL
oligonu-cleotide	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Characterization	NULL
of	NULL
site	NULL
C	NULL
complexes	NULL
produced	NULL
with	NULL
DG75	NULL
or	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
using	NULL
an	NULL
antibody	NULL
(	NULL
Ab	NULL
)	NULL
directed	NULL
against	NULL
specific	NULL
RFX	NULL
or	NULL
MIBP1	NULL
polypeptides	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
probe	NULL
plus	NULL
nuclear	NULL
extract	NULL
alone	NULL
showing	NULL
three	NULL
major	NULL
complexes	NULL
,	NULL
c	NULL
'	NULL
,	NULL
c	NULL
``	NULL
,	NULL
and	NULL
c	NULL
``	NULL
;	NULL
lanes	NULL
2	NULL
to	NULL
6	NULL
,	NULL
probe	NULL
plus	NULL
nuclear	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
antibody	NULL
against	NULL
the	NULL
indicated	NULL
proteins	NULL
.	NULL

nuclear	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
unlabeled	NULL
competitor	NULL
sequences	NULL
containing	NULL
known	NULL
RFX/MIBP1	NULL
binding	NULL
sites	NULL
.	NULL

These	NULL
competitors	NULL
,	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
are	NULL
derived	NULL
from	NULL
the	NULL
RFX	NULL
binding	NULL
sequences	NULL
at	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
enhancer	NULL
I	NULL
(	NULL
HBV	NULL
enh-I	NULL
)	NULL
,	NULL
the	NULL
MIBP1	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
first	NULL
intron	NULL
of	NULL
the	NULL
human	NULL
mye	NULL
promoter	NULL
(	NULL
MIF-1	NULL
)	NULL
,	NULL
and	NULL
the	NULL
X	NULL
box	NULL
sequence	NULL
from	NULL
EBV	NULL
PROMOTER	NULL
REGULATION	NULL
BY	NULL
RFX	NULL
AND	NULL
BSAP	NULL
-	NULL
10461	NULL
the	NULL
human	NULL
HLA	NULL
class	NULL
II	NULL
DRA	NULL
promoter	NULL
(	NULL
HLA	NULL
DRA	NULL
X	NULL
)	NULL
.	NULL

The	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
demonstrate	NULL
that	NULL
the	NULL
formation	NULL
of	NULL
site	NULL
C	NULL
complexes	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
DG75	NULL
(	NULL
B-cell	NULL
)	NULL
and	NULL
Jurkat	NULL
(	NULL
T-cell	NULL
)	NULL
nuclear	NULL
extracts	NULL
was	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
HBV	NULL
enh-I	NULL
,	NULL
MIF-1	NULL
,	NULL
and	NULL
HLA	NULL
DRA	NULL
X	NULL
competitor	NULL
oligonucle-otides	NULL
,	NULL
as	NULL
well	NULL
as	NULL
by	NULL
addition	NULL
of	NULL
a	NULL
site	NULL
C	NULL
competitor	NULL
itself	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
mutant	NULL
sequences	NULL
HBV	NULL
enh-I	NULL
m	NULL
and	NULL
MIF-1	NULL
m	NULL
,	NULL
previously	NULL
reported	NULL
to	NULL
have	NULL
lost	NULL
RFX/MIBP1	NULL
binding	NULL
(	NULL
45	NULL
)	NULL
,	NULL
and	NULL
the	NULL
mutant	NULL
site	NULL
C	NULL
sequence	NULL
m1	NULL
(	NULL
6	NULL
)	NULL
were	NULL
unable	NULL
to	NULL
compete	NULL
.	NULL

These	NULL
findings	NULL
provide	NULL
the	NULL
first	NULL
evidence	NULL
that	NULL
site	NULL
C	NULL
is	NULL
indeed	NULL
a	NULL
functional	NULL
RFX	NULL
binding	NULL
site	NULL
.	NULL

We	NULL
next	NULL
used	NULL
specific	NULL
antisera	NULL
raised	NULL
against	NULL
individual	NULL
RFX	NULL
proteins	NULL
to	NULL
identify	NULL
which	NULL
of	NULL
these	NULL
factors	NULL
was	NULL
binding	NULL
site	NULL
C	NULL
in	NULL
our	NULL
in	NULL
vitro	NULL
assays	NULL
.	NULL

The	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

2C	NULL
show	NULL
that	NULL
the	NULL
largest	NULL
complex	NULL
,	NULL
c	NULL
'	NULL
,	NULL
was	NULL
shifted	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
MIBP1	NULL
antibody	NULL
and	NULL
its	NULL
formation	NULL
was	NULL
blocked	NULL
by	NULL
an	NULL
RFX1	NULL
antibody	NULL
.	NULL

A	NULL
second	NULL
complex	NULL
,	NULL
c	NULL
``	NULL
,	NULL
was	NULL
blocked	NULL
by	NULL
antibodies	NULL
against	NULL
RFX1	NULL
and	NULL
RFX3	NULL
,	NULL
while	NULL
a	NULL
third	NULL
complex	NULL
,	NULL
c	NULL
,	NULL
though	NULL
weaker	NULL
,	NULL
appeared	NULL
to	NULL
be	NULL
blocked	NULL
by	NULL
an	NULL
antibody	NULL
against	NULL
RFX3	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
there	NULL
were	NULL
no	NULL
detectable	NULL
differences	NULL
in	NULL
complex	NULL
formation	NULL
or	NULL
mobility	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
RFXS5	NULL
antibody	NULL
or	NULL
a	NULL
control	NULL
Oct-1	NULL
antibody	NULL
.	NULL

These	NULL
findings	NULL
indicate	NULL
that	NULL
RFX1	NULL
,	NULL
RFX3	NULL
,	NULL
and	NULL
MIBP1	NULL
present	NULL
in	NULL
DG75	NULL
nuclear	NULL
extracts	NULL
can	NULL
interact	NULL
with	NULL
the	NULL
site	NULL
C	NULL
sequence	NULL
in	NULL
a	NULL
combination	NULL
of	NULL
homodimeric	NULL
and	NULL
heterodimeric	NULL
complexes	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
,	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
that	NULL
these	NULL
RFX	NULL
factors	NULL
are	NULL
ubiquitously	NULL
expressed	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Effect	NULL
of	NULL
mutations	NULL
in	NULL
site	NULL
C	NULL
on	NULL
RFX	NULL
binding	NULL
and	NULL
Wp	NULL
activity	NULL
.	NULL

Although	NULL
the	NULL
RFX	NULL
consensus	NULL
binding	NULL
motif	NULL
contains	NULL
a	NULL
palindromic	NULL
sequence	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
in	NULL
certain	NULL
cases	NULL
RFX	NULL
proteins	NULL
can	NULL
bind	NULL
as	NULL
monomers	NULL
rather	NULL
than	NULL
dimers	NULL
and	NULL
that	NULL
one	NULL
half	NULL
of	NULL
the	NULL
binding	NULL
motif	NULL
may	NULL
be	NULL
sufficient	NULL
for	NULL
the	NULL
interaction	NULL
(	NULL
8	NULL
,	NULL
10	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
investigated	NULL
the	NULL
sequence	NULL
requirements	NULL
for	NULL
RFX	NULL
complex	NULL
formation	NULL
at	NULL
Wp	NULL
by	NULL
introducing	NULL
a	NULL
series	NULL
of	NULL
base	NULL
substitutions	NULL
throughout	NULL
site	NULL
C	NULL
and	NULL
then	NULL
using	NULL
each	NULL
of	NULL
these	NULL
mutant	NULL
sequences	NULL
(	NULL
m1	NULL
to	NULL
m4	NULL
[	NULL
Fig	NULL
.	NULL

3A	NULL
]	NULL
)	NULL
as	NULL
competitor	NULL
in	NULL
a	NULL
bandshift	NULL
assay	NULL
.	NULL

The	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
show	NULL
that	NULL
m1	NULL
and	NULL
m2	NULL
were	NULL
unable	NULL
to	NULL
compete	NULL
for	NULL
factor	NULL
binding	NULL
,	NULL
m3	NULL
led	NULL
to	NULL
a	NULL
partial	NULL
reduction	NULL
in	NULL
binding	NULL
,	NULL
while	NULL
m4	NULL
competed	NULL
as	NULL
effectively	NULL
as	NULL
the	NULL
wild-type	NULL
sequence	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
Wp	NULL
sequences	NULL
in	NULL
the	NULL
half-site	NULL
between	NULL
-125	NULL
and	NULL
-116	NULL
were	NULL
the	NULL
more	NULL
important	NULL
for	NULL
RFX	NULL
binding	NULL
.	NULL

To	NULL
further	NULL
investigate	NULL
if	NULL
binding	NULL
to	NULL
site	NULL
C	NULL
requires	NULL
one	NULL
or	NULL
both	NULL
half-sites	NULL
,	NULL
we	NULL
synthesized	NULL
two	NULL
additional	NULL
competitors	NULL
carrying	NULL
truncated	NULL
site	NULL
C	NULL
sequenc-es	NULL
:	NULL
LH	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
5	NULL
'	NULL
half-site	NULL
sequence	NULL
(	NULL
-125	NULL
to	NULL
-113	NULL
)	NULL
;	NULL
and	NULL
RH	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
3	NULL
'	NULL
sequence	NULL
(	NULL
-119	NULL
to	NULL
-107	NULL
)	NULL
.	NULL

The	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

3C	NULL
show	NULL
that	NULL
the	NULL
LH	NULL
,	NULL
but	NULL
not	NULL
the	NULL
RH	NULL
,	NULL
sequence	NULL
was	NULL
sufficient	NULL
to	NULL
compete	NULL
for	NULL
RFX	NULL
binding	NULL
to	NULL
site	NULL
C.	NULL
This	NULL
result	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
bandshift	NULL
data	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
and	NULL
also	NULL
accounts	NULL
for	NULL
our	NULL
earlier	NULL
observation	NULL
that	NULL
the	NULL
minimum	NULL
sequences	NULL
for	NULL
site	NULL
C	NULL
binding	NULL
are	NULL
located	NULL
between	NULL
-125	NULL
and	NULL
-111	NULL
(	NULL
6	NULL
)	NULL
.	NULL

We	NULL
then	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
m1	NULL
to	NULL
m4	NULL
on	NULL
Wp	NULL
activity	NULL
in	NULL
a	NULL
transient	NULL
assay	NULL
system	NULL
using	NULL
the	NULL
Wp440	NULL
reporter	NULL
construct	NULL
that	NULL
includes	NULL
both	NULL
the	NULL
UAS1	NULL
and	NULL
UAS2	NULL
regions	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
the	NULL
B-cell	NULL
line	NULL
DG75	NULL
,	NULL
introduction	NULL
of	NULL
mutations	NULL
m1	NULL
and	NULL
m2	NULL
,	NULL
which	NULL
blocked	NULL
RFX	NULL
binding	NULL
in	NULL
vitro	NULL
,	NULL
decreased	NULL
Wp	NULL
activity	NULL
seven-	NULL
to	NULL
ninefold	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
m3	NULL
and	NULL
m4	NULL
changes	NULL
had	NULL
little	NULL
if	NULL
any	NULL
effect	NULL
both	NULL
on	NULL
RFX	NULL
binding	NULL
and	NULL
on	NULL
promoter	NULL
function	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
we	NULL
repeated	NULL
this	NULL
experiment	NULL
using	NULL
the	NULL
non-B-cell	NULL
line	NULL
K562	NULL
,	NULL
in	NULL
which	NULL
the	NULL
B-cell-specific	NULL
UAS1	NULL
region	NULL
of	NULL
Wp	NULL
is	NULL
not	NULL
operational	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
Wp	NULL
activity	NULL
was	NULL
much	NULL
lower	NULL
but	NULL
was	NULL
not	NULL
affected	NULL
significantly	NULL
by	NULL
any	NULL
of	NULL
the	NULL
site	NULL
C	NULL
mutations	NULL
.	NULL

Taken	NULL
together	NULL
with	NULL
the	NULL
results	NULL
of	NULL
the	NULL
bandshift	NULL
studies	NULL
,	NULL
these	NULL
findings	NULL
strongly	NULL
imply	NULL
that	NULL
RFX	NULL
proteins	NULL
are	NULL
involved	NULL
in	NULL
B-cell-specific	NULL
activation	NULL
of	NULL
Wp	NULL
.	NULL

10462	NULL
TIERNEY	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
125	NULL
-p	NULL
_	NULL
<	NULL
-	NULL
-99	NULL
Wp	NULL
Site	NULL
C	NULL
CGCGTTGCTAGGCCACCTTCTCAGTCC	NULL
m1	NULL
CGCGTACCTAGGCCACCTTCTCAGTCC	NULL
m2	NULL
CGCGTTGCATGGCCACCTTCTCAGTCC	NULL
m3	NULL
CGCGTTGCTAGTCCACCTTCTCAGTCC	NULL
m4	NULL
CGCGTTGCTAGGCGTCCTTCTCAGTCC	NULL
LH	NULL
CGCGTTGCTAGGC	NULL
RH	NULL
GCTAGGCCACCTT	NULL
B	NULL
C	NULL
Competitor	NULL
3	NULL
3	NULL
®	NULL
&	NULL
&	NULL
&	NULL
z	NULL
5	NULL
1	NULL
2	NULL
D	NULL
4000	NULL
DG75	NULL
K562	NULL
p	NULL
#	NULL
3000	NULL
B	NULL
E	NULL
2000	NULL
9g	NULL
1000	NULL
0	NULL
P22	NULL
)	NULL
F774	NULL
727A	NULL
orn	NULL
$	NULL
m	NULL
f	NULL
f	NULL
I	NULL
$	NULL
o	NULL
:	NULL
f	NULL
f	NULL
I	NULL
=	NULL
O	NULL
0	NULL
O	NULL
0	NULL
s	NULL
o	NULL
0	NULL
O	NULL
D	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
site	NULL
C.	NULL
(	NULL
A	NULL
)	NULL
Nucleotide	NULL
sequences	NULL
of	NULL
wild-type	NULL
and	NULL
mutated	NULL
(	NULL
m1	NULL
to	NULL
m4	NULL
)	NULL
site	NULL
C	NULL
competitors	NULL
used	NULL
in	NULL
bandshift	NULL
experiments	NULL
;	NULL
nucleotide	NULL
substitutions	NULL
are	NULL
shaded	NULL
.	NULL

Also	NULL
shown	NULL
are	NULL
two	NULL
truncated	NULL
site	NULL
C	NULL
fragments	NULL
which	NULL
carry	NULL
either	NULL
the	NULL
5	NULL
'	NULL
(	NULL
LH	NULL
)	NULL
or	NULL
3	NULL
``	NULL
(	NULL
RH	NULL
)	NULL
half-site	NULL
sequence	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Effect	NULL
of	NULL
mutations	NULL
m1	NULL
to	NULL
m4	NULL
on	NULL
RFX/MIBP1	NULL
binding	NULL
to	NULL
site	NULL
C.	NULL
Lanes	NULL
1	NULL
to	NULL
5	NULL
,	NULL
protein-DNA	NULL
complexes	NULL
obtained	NULL
by	NULL
incubating	NULL
a	NULL
site	NULL
C	NULL
probe	NULL
with	NULL
DG75	NULL
nuclear	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
mutant	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
or	NULL
wild-type	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
competitor	NULL
sequence	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
probe	NULL
plus	NULL
nuclear	NULL
extract	NULL
alone	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Experiment	NULL
similar	NULL
to	NULL
that	NULL
shown	NULL
in	NULL
panel	NULL
B	NULL
but	NULL
including	NULL
the	NULL
truncated	NULL
site	NULL
C	NULL
fragments	NULL
LH	NULL
and	NULL
RH	NULL
as	NULL
competitors	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Effect	NULL
of	NULL
site	NULL
C	NULL
mutations	NULL
on	NULL
Wp	NULL
activity	NULL
.	NULL

Promoter	NULL
activity	NULL
was	NULL
assayed	NULL
by	NULL
quantifying	NULL
luciferase	NULL
expression	NULL
(	NULL
as	NULL
relative	NULL
light	NULL
units	NULL
[	NULL
RLU	NULL
]	NULL
)	NULL
in	NULL
DG75	NULL
and	NULL
in	NULL
K562	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
a	NULL
wild-type	NULL
Wp	NULL
reporter	NULL
(	NULL
Wp440	NULL
)	NULL
or	NULL
with	NULL
mutant	NULL
derivatives	NULL
carrying	NULL
m1	NULL
to	NULL
m4	NULL
shown	NULL
above	NULL
.	NULL

The	NULL
reported	NULL
luciferase	NULL
values	NULL
are	NULL
the	NULL
means	NULL
+	NULL
standard	NULL
deviations	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Site	NULL
B	NULL
and	NULL
site	NULL
D	NULL
are	NULL
binding	NULL
sites	NULL
for	NULL
the	NULL
same	NULL
B-cell-specific	NULL
cellular	NULL
protein	NULL
.	NULL

We	NULL
then	NULL
analyzed	NULL
the	NULL
two	NULL
sites	NULL
within	NULL
UAS1	NULL
which	NULL
bound	NULL
B-cell-specific	NULL
factors	NULL
in	NULL
the	NULL
initial	NULL
bandshift	NULL
studies	NULL
:	NULL
site	NULL
B	NULL
(	NULL
already	NULL
identified	NULL
as	NULL
-115	NULL
to	NULL
-86	NULL
)	NULL
and	NULL
the	NULL
newly	NULL
identified	NULL
site	NULL
D	NULL
,	NULL
which	NULL
lay	NULL
within	NULL
the	NULL
Wp	NULL
-264/-135	NULL
probe	NULL
used	NULL
in	NULL
the	NULL
first	NULL
experiments	NULL
(	NULL
Fig	NULL
.	NULL

1c	NULL
)	NULL
.	NULL

Further	NULL
bandshift	NULL
studies	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
this	NULL
latter	NULL
probe	NULL
and	NULL
a	NULL
series	NULL
of	NULL
shorter	NULL
oligonucleotide	NULL
competitors	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
this	NULL
localized	NULL
site	NULL
D	NULL
to	NULL
the	NULL
-242	NULL
to	NULL
-215	NULL
region	NULL
,	NULL
that	NULL
being	NULL
the	NULL
shortest	NULL
sequence	NULL
capable	NULL
of	NULL
fully	NULL
competing	NULL
out	NULL
binding	NULL
of	NULL
the	NULL
B-cell-specific	NULL
factor	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

Although	NULL
there	NULL
was	NULL
no	NULL
immediate	NULL
homology	NULL
apparent	NULL
between	NULL
the	NULL
site	NULL
D	NULL
and	NULL
site	NULL
B	NULL
sequences	NULL
,	NULL
we	NULL
carried	NULL
out	NULL
a	NULL
series	NULL
of	NULL
cross-competition	NULL
assays	NULL
to	NULL
examine	NULL
whether	NULL
the	NULL
two	NULL
sites	NULL
were	NULL
binding	NULL
the	NULL
same	NULL
or	NULL
different	NULL
B-cell-specific	NULL
proteins	NULL
.	NULL

These	NULL
assays	NULL
included	NULL
as	NULL
competitors	NULL
the	NULL
wild-type	NULL
site	NULL
D	NULL
and	NULL
site	NULL
B	NULL
sequences	NULL
and	NULL
derived	NULL
mutant	NULL
sequences	NULL
known	NULL
to	NULL
have	NULL
lost	NULL
binding	NULL
activity	NULL
(	NULL
reference	NULL
6	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

4C	NULL
(	NULL
top	NULL
gel	NULL
)	NULL
show	NULL
that	NULL
formation	NULL
of	NULL
the	NULL
site	NULL
D-specific	NULL
complex	NULL
was	NULL
inhibited	NULL
in	NULL
a	NULL
concentration-dependent	NULL
manner	NULL
both	NULL
by	NULL
site	NULL
D	NULL
and	NULL
site	NULL
B	NULL
competitors	NULL
,	NULL
while	NULL
the	NULL
rele-	NULL
A	NULL
3	NULL
§	NULL
8	NULL
H	NULL
~254/-220	NULL
+242/-215	NULL
-237/-215	NULL
-232/-215	NULL
wn	NULL
T	NULL
a	NULL
<	NULL
#	NULL
05	NULL
Pal	NULL
iD	NULL
B	NULL
-242	NULL
-215	NULL
Site	NULL
D	NULL
GCGGGTCTATGGTTGGCTGCGCTGCTGC	NULL
Site	NULL
D	NULL
m1	NULL
-	NULL
GCGGGTCTATCCTTGGCTGCGCTGCTGC	NULL
Site	NULL
D	NULL
m2	NULL
-	NULL
GCGGGTCTATGGTTCCCTGCGCTGCTGC	NULL
115	NULL
90	NULL
GGCCACCTTCTCAGTCCAGCGCGTTT	NULL
GGCCACCTTCTCAGTCCACGGCGTTT	NULL
Site	NULL
B	NULL
Site	NULL
B	NULL
m	NULL
Akata	NULL
+	NULL
competitor	NULL
000	NULL
Site	NULL
D	NULL
x1000	NULL
Site	NULL
D	NULL
m1	NULL
x1000	NULL
Site	NULL
D	NULL
m2	NULL
x1000	NULL
§	NULL
x	NULL
m	NULL
#	NULL
a	NULL
Site	NULL
D	NULL
x100	NULL
Site	NULL
D	NULL
x10	NULL
C	NULL
3	NULL
[	NULL
esl	NULL
#	NULL
a	NULL
Site	NULL
B	NULL
x100	NULL
Site	NULL
B	NULL
x10	NULL
BC	NULL
»	NULL
10	NULL
20030	NULL
40	NULL
5	NULL
60	NULL
70	NULL
%	NULL
9	NULL
G0	NULL
11	NULL
12	NULL
13	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Binding	NULL
of	NULL
cellular	NULL
factors	NULL
to	NULL
sites	NULL
D	NULL
and	NULL
B	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Determination	NULL
of	NULL
the	NULL
minimal	NULL
sequence	NULL
required	NULL
for	NULL
factor	NULL
binding	NULL
to	NULL
site	NULL
D.	NULL
Lanes	NULL
represent	NULL
protein-DNA	NULL
complexes	NULL
obtained	NULL
by	NULL
incubating	NULL
DG75	NULL
nuclear	NULL
extract	NULL
with	NULL
the	NULL
Wp	NULL
-264/-135	NULL
probe	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
competitor	NULL
oligonucleotides	NULL
carrying	NULL
the	NULL
Wp	NULL
sequences	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
Sites	NULL
D	NULL
and	NULL
B	NULL
interact	NULL
with	NULL
the	NULL
same	NULL
B-cell-specific	NULL
factor	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Minimal	NULL
nucleotide	NULL
sequence	NULL
required	NULL
for	NULL
factor	NULL
binding	NULL
to	NULL
sites	NULL
D	NULL
and	NULL
B	NULL
,	NULL
along	NULL
with	NULL
sequences	NULL
of	NULL
mutant	NULL
derivatives	NULL
of	NULL
site	NULL
D	NULL
(	NULL
Dm1	NULL
and	NULL
Dm2	NULL
)	NULL
and	NULL
site	NULL
B	NULL
(	NULL
Bm	NULL
)	NULL
known	NULL
to	NULL
have	NULL
lost	NULL
factor	NULL
binding	NULL
.	NULL

Nucleotide	NULL
substitutions	NULL
are	NULL
shaded	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Protein-DNA	NULL
complexes	NULL
obtained	NULL
by	NULL
incubating	NULL
the	NULL
minimal	NULL
site	NULL
D	NULL
probe	NULL
with	NULL
the	NULL
indicated	NULL
nuclear	NULL
extracts	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
wild-type	NULL
or	NULL
mutant	NULL
competitor	NULL
oligonucleotide	NULL
added	NULL
at	NULL
1,000-	NULL
,	NULL
100-	NULL
or	NULL
10-fold	NULL
,	NULL
molar	NULL
excess	NULL
,	NULL
as	NULL
shown	NULL
(	NULL
top	NULL
)	NULL
,	NULL
and	NULL
a	NULL
parallel	NULL
experiment	NULL
using	NULL
a	NULL
site	NULL
B	NULL
probe	NULL
(	NULL
bottom	NULL
)	NULL
.	NULL

Vor	NULL
.	NULL

74	NULL
,	NULL
2000	NULL
GA	NULL
,	NULL
GG	NULL
A	NULL
BSAP	NULL
consensus	NULL
ennCAnTGnnGCGT	NULL
aA	NULL
CCh	NULL
H2B	NULL
2.1	NULL
CGCCGGAGCACTGATGCAGCGCGGATCC	NULL
Site	NULL
D	NULL
GCGGGTETATGGTTG	NULL
@	NULL
CTac	NULL
@	NULL
ctoctoc	NULL
Site	NULL
B	NULL
GGCCcaceTTctcaotcEAGcoCerTracet	NULL
B	NULL
ion-B	NULL
ae	NULL
B	NULL
cell	NULL
DG75	NULL
IVT	NULL
BSAP	NULL
§	NULL
§	NULL
a	NULL
1a	NULL
§	NULL
§	NULL
xx	NULL
<	NULL
~2mxx22	NULL
8	NULL
§	NULL
8	NULL
8	NULL
$	NULL
$	NULL
8	NULL
tE	NULL
&	NULL
&	NULL
B	NULL
F	NULL
3	NULL
H2B	NULL
2.1	NULL
>	NULL
Io	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
70	NULL
80	NULL
9	NULL
40	NULL
I1	NULL
42	NULL
13	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Interaction	NULL
of	NULL
BSAP	NULL
with	NULL
sites	NULL
D	NULL
and	NULL
B	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Sequence	NULL
comparison	NULL
of	NULL
a	NULL
published	NULL
consensus	NULL
BSAP	NULL
binding	NULL
site	NULL
(	NULL
9	NULL
)	NULL
,	NULL
the	NULL
known	NULL
BSAP	NULL
site	NULL
present	NULL
at	NULL
the	NULL
sea	NULL
urchin	NULL
late	NULL
histone	NULL
promoter	NULL
(	NULL
H2B	NULL
2.1	NULL
)	NULL
,	NULL
and	NULL
EBV	NULL
sites	NULL
D	NULL
and	NULL
B.	NULL
Shaded	NULL
nucleotides	NULL
indicate	NULL
positions	NULL
matching	NULL
the	NULL
consensus	NULL
sequence	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Protein-DNA	NULL
complexes	NULL
obtained	NULL
by	NULL
incubating	NULL
the	NULL
H2B	NULL
2.1	NULL
(	NULL
top	NULL
)	NULL
,	NULL
site	NULL
D	NULL
(	NULL
middle	NULL
)	NULL
,	NULL
and	NULL
site	NULL
B	NULL
(	NULL
bottom	NULL
)	NULL
probes	NULL
with	NULL
either	NULL
nuclear	NULL
extracts	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
8	NULL
)	NULL
or	NULL
IVT	NULL
BSAP	NULL
protein	NULL
(	NULL
lanes	NULL
9	NULL
to	NULL
13	NULL
)	NULL
.	NULL

Lanes	NULL
1	NULL
to	NULL
4	NULL
,	NULL
probe	NULL
plus	NULL
the	NULL
indicated	NULL
nuclear	NULL
extract	NULL
;	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
,	NULL
probe	NULL
and	NULL
DG75	NULL
nuclear	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
competitor	NULL
oligonucleotide	NULL
;	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
probe	NULL
plus	NULL
DG75	NULL
nuclear	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
BSAP-specific	NULL
or	NULL
YY1-specific	NULL
antiserum	NULL
;	NULL
lane	NULL
9	NULL
,	NULL
probe	NULL
and	NULL
IVT	NULL
BSAP	NULL
;	NULL
lanes	NULL
10	NULL
to	NULL
13	NULL
,	NULL
same	NULL
as	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
but	NULL
with	NULL
IVT	NULL
BSAP	NULL
replacing	NULL
DG75	NULL
nuclear	NULL
extract	NULL
.	NULL

vant	NULL
mutant	NULL
sequences	NULL
did	NULL
not	NULL
compete	NULL
.	NULL

The	NULL
corresponding	NULL
experiment	NULL
looking	NULL
at	NULL
binding	NULL
to	NULL
a	NULL
site	NULL
B	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
bottom	NULL
gel	NULL
)	NULL
likewise	NULL
showed	NULL
concentration-dependent	NULL
competition	NULL
by	NULL
both	NULL
site	NULL
D	NULL
and	NULL
site	NULL
B	NULL
competitors	NULL
but	NULL
not	NULL
by	NULL
the	NULL
mutant	NULL
oligonucleotides	NULL
.	NULL

In	NULL
both	NULL
assays	NULL
,	NULL
at	NULL
low	NULL
concentrations	NULL
the	NULL
site	NULL
D	NULL
sequence	NULL
was	NULL
a	NULL
more	NULL
effective	NULL
competitor	NULL
than	NULL
the	NULL
site	NULL
B	NULL
sequence	NULL
.	NULL

These	NULL
findings	NULL
strongly	NULL
imply	NULL
that	NULL
the	NULL
same	NULL
B-cell-specific	NULL
protein	NULL
was	NULL
binding	NULL
to	NULL
both	NULL
sites	NULL
,	NULL
though	NULL
with	NULL
higher	NULL
affinity	NULL
to	NULL
the	NULL
site	NULL
D	NULL
sequence	NULL
.	NULL

Identification	NULL
of	NULL
sites	NULL
B	NULL
and	NULL
D	NULL
as	NULL
binding	NULL
sites	NULL
for	NULL
B-cell-specific	NULL
activator	NULL
protein	NULL
BSAP/Pax-5	NULL
.	NULL

Searching	NULL
databases	NULL
of	NULL
known	NULL
transcription	NULL
factor	NULL
binding	NULL
motifs	NULL
revealed	NULL
a	NULL
limited	NULL
homology	NULL
between	NULL
the	NULL
site	NULL
D	NULL
sequence	NULL
and	NULL
a	NULL
consensus	NULL
motif	NULL
(	NULL
9	NULL
)	NULL
for	NULL
the	NULL
B-cell-specific	NULL
transcription	NULL
factor	NULL
BSAP/Pax5	NULL
(	NULL
Fig	NULL
.	NULL

SA	NULL
)	NULL
.	NULL

There	NULL
was	NULL
also	NULL
a	NULL
lesser	NULL
degree	NULL
of	NULL
sequence	NULL
homology	NULL
between	NULL
this	NULL
BSAP	NULL
consensus	NULL
and	NULL
site	NULL
B	NULL
,	NULL
although	NULL
this	NULL
would	NULL
not	NULL
have	NULL
been	NULL
considered	NULL
significant	NULL
had	NULL
we	NULL
not	NULL
already	NULL
known	NULL
EBV	NULL
PROMOTER	NULL
REGULATION	NULL
BY	NULL
RFX	NULL
AND	NULL
BSAP	NULL
-	NULL
10463	NULL
that	NULL
sites	NULL
B	NULL
and	NULL
D	NULL
bound	NULL
the	NULL
same	NULL
protein	NULL
.	NULL

BSAP	NULL
,	NULL
a	NULL
mammalian	NULL
homologue	NULL
of	NULL
the	NULL
sea	NULL
urchin	NULL
tissue-specific	NULL
activator	NULL
protein	NULL
(	NULL
4	NULL
)	NULL
,	NULL
was	NULL
originally	NULL
identified	NULL
by	NULL
its	NULL
ability	NULL
to	NULL
interact	NULL
with	NULL
conserved	NULL
regulatory	NULL
sequences	NULL
upstream	NULL
of	NULL
late	NULL
histone	NULL
genes	NULL
(	NULL
5	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
carried	NULL
out	NULL
bandshift	NULL
assays	NULL
to	NULL
determine	NULL
if	NULL
these	NULL
site	NULL
B	NULL
and	NULL
site	NULL
D	NULL
sequences	NULL
could	NULL
compete	NULL
for	NULL
BSAP	NULL
binding	NULL
to	NULL
the	NULL
sea	NULL
urchin	NULL
histone	NULL
promoter-derived	NULL
oligonucleotide	NULL
probe	NULL
H2B	NULL
2.1	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

5B	NULL
(	NULL
top	NULL
)	NULL
show	NULL
that	NULL
the	NULL
H2B	NULL
2.1	NULL
probe	NULL
formed	NULL
a	NULL
specific	NULL
complex	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
nuclear	NULL
extract	NULL
prepared	NULL
from	NULL
the	NULL
B-cell	NULL
lines	NULL
Ramos	NULL
and	NULL
DG75	NULL
,	NULL
but	NULL
not	NULL
in	NULL
extracts	NULL
from	NULL
the	NULL
T-cell	NULL
lines	NULL
CEM	NULL
and	NULL
Jurkat	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
B-cell-restricted	NULL
expression	NULL
of	NULL
BSAP	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
formation	NULL
of	NULL
this	NULL
complex	NULL
was	NULL
abrogated	NULL
by	NULL
either	NULL
site	NULL
B	NULL
or	NULL
site	NULL
D	NULL
competitor	NULL
,	NULL
implying	NULL
that	NULL
the	NULL
same	NULL
B-cell-restricted	NULL
factor	NULL
interacted	NULL
with	NULL
all	NULL
three	NULL
sites	NULL
.	NULL

This	NULL
was	NULL
confirmed	NULL
in	NULL
parallel	NULL
experiments	NULL
,	NULL
in	NULL
which	NULL
incubation	NULL
of	NULL
B-cell	NULL
nuclear	NULL
extract	NULL
with	NULL
a	NULL
site	NULL
D	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
middle	NULL
)	NULL
or	NULL
site	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
bottom	NULL
)	NULL
probe	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
complex	NULL
with	NULL
electro-phoretic	NULL
mobility	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
complex	NULL
formed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
H2B	NULL
2.1	NULL
probe	NULL
.	NULL

Supershift	NULL
assays	NULL
further	NULL
confirmed	NULL
that	NULL
the	NULL
complexes	NULL
formed	NULL
by	NULL
all	NULL
three	NULL
probes	NULL
contained	NULL
BSAP	NULL
;	NULL
thus	NULL
,	NULL
addition	NULL
of	NULL
a	NULL
-specific	NULL
polyclonal	NULL
antibody	NULL
led	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
complex	NULL
formation	NULL
in	NULL
all	NULL
three	NULL
cases	NULL
,	NULL
whereas	NULL
a	NULL
control	NULL
YY1-specific	NULL
antibody	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
IVT	NULL
BSAP	NULL
formed	NULL
a	NULL
single	NULL
complex	NULL
with	NULL
the	NULL
H2B	NULL
2.1	NULL
,	NULL
site	NULL
D	NULL
,	NULL
and	NULL
site	NULL
B	NULL
probes	NULL
,	NULL
which	NULL
in	NULL
each	NULL
case	NULL
comigrated	NULL
with	NULL
that	NULL
formed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
B-cell	NULL
nuclear	NULL
extract	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
these	NULL
complexes	NULL
with	NULL
IVT	NULL
protein	NULL
were	NULL
abrogated	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
either	NULL
site	NULL
B	NULL
or	NULL
site	NULL
D	NULL
competitor	NULL
or	NULL
an	NULL
anti-BSAP	NULL
antibody	NULL
,	NULL
confirming	NULL
that	NULL
the	NULL
B-cell-specific	NULL
factor	NULL
which	NULL
binds	NULL
to	NULL
these	NULL
Wp	NULL
sites	NULL
is	NULL
BSAP	NULL
.	NULL

Effect	NULL
of	NULL
BSAP	NULL
binding	NULL
on	NULL
Wp	NULL
activity	NULL
.	NULL

Having	NULL
demonstrated	NULL
that	NULL
BSAP	NULL
binds	NULL
to	NULL
two	NULL
sites	NULL
in	NULL
Wp	NULL
,	NULL
we	NULL
next	NULL
determined	NULL
the	NULL
contribution	NULL
of	NULL
these	NULL
sites	NULL
to	NULL
Wp	NULL
activity	NULL
in	NULL
different	NULL
B	NULL
and	NULL
non-B-cell	NULL
lines	NULL
.	NULL

The	NULL
Bm	NULL
(	NULL
site	NULL
B	NULL
)	NULL
and	NULL
Dm1	NULL
and	NULL
Dm2	NULL
(	NULL
site	NULL
D	NULL
)	NULL
mutations	NULL
,	NULL
known	NULL
to	NULL
abrogate	NULL
BSAP	NULL
binding	NULL
in	NULL
vitro	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
,	NULL
were	NULL
introduced	NULL
either	NULL
singly	NULL
or	NULL
in	NULL
combination	NULL
into	NULL
the	NULL
Wp440	NULL
luciferase	NULL
reporter	NULL
.	NULL

The	NULL
activities	NULL
of	NULL
the	NULL
wild-type	NULL
and	NULL
mutant	NULL
promoter	NULL
constructs	NULL
were	NULL
then	NULL
compared	NULL
in	NULL
transient	NULL
transfection	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

In	NULL
the	NULL
three	NULL
B-cell	NULL
lines	NULL
tested	NULL
(	NULL
Akata	NULL
,	NULL
Ramos	NULL
,	NULL
and	NULL
DG75	NULL
)	NULL
,	NULL
mutation	NULL
of	NULL
either	NULL
site	NULL
B	NULL
or	NULL
site	NULL
D	NULL
led	NULL
to	NULL
a	NULL
three-	NULL
to	NULL
fourfold	NULL
drop	NULL
in	NULL
luciferase	NULL
expression	NULL
compared	NULL
to	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
wild-type	NULL
Wp	NULL
440	NULL
reporter	NULL
.	NULL

However	NULL
,	NULL
there	NULL
was	NULL
an	NULL
even	NULL
greater	NULL
reduction	NULL
of	NULL
5-	NULL
to	NULL
10-fold	NULL
when	NULL
both	NULL
BSAP	NULL
binding	NULL
sites	NULL
were	NULL
mutated	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
when	NULL
the	NULL
experiments	NULL
were	NULL
repeated	NULL
in	NULL
the	NULL
non-B-cell	NULL
lines	NULL
K562	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
and	NULL
CEM	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
mutation	NULL
of	NULL
either	NULL
one	NULL
or	NULL
both	NULL
BSAP	NULL
binding	NULL
sites	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
low	NULL
basal	NULL
levels	NULL
of	NULL
promoter	NULL
activity	NULL
.	NULL

While	NULL
the	NULL
above	NULL
results	NULL
strongly	NULL
suggested	NULL
that	NULL
BSAP	NULL
binding	NULL
to	NULL
sites	NULL
B	NULL
and	NULL
D	NULL
is	NULL
critical	NULL
for	NULL
optimal	NULL
Wp	NULL
activity	NULL
in	NULL
B-cell	NULL
lines	NULL
,	NULL
we	NULL
sought	NULL
independent	NULL
evidence	NULL
that	NULL
BSAP	NULL
could	NULL
directly	NULL
activate	NULL
Wp	NULL
.	NULL

Figure	NULL
6B	NULL
shows	NULL
the	NULL
results	NULL
of	NULL
experiments	NULL
in	NULL
which	NULL
a	NULL
BSAP	NULL
expression	NULL
vector	NULL
BSAP/SGS	NULL
(	NULL
or	NULL
the	NULL
empty	NULL
vector	NULL
pSGS	NULL
as	NULL
a	NULL
control	NULL
)	NULL
was	NULL
cotransfected	NULL
with	NULL
a	NULL
reporter	NULL
construct	NULL
containing	NULL
Wp	NULL
sequences	NULL
with	NULL
either	NULL
wild-type	NULL
or	NULL
mutated	NULL
BSAP	NULL
sites	NULL
.	NULL

In	NULL
the	NULL
B-cell	NULL
lines	NULL
DG75	NULL
(	NULL
already	NULL
BSAP	NULL
positive	NULL
)	NULL
,	NULL
cotransfection	NULL
of	NULL
the	NULL
wild-type	NULL
Wp440	NULL
reporter	NULL
and	NULL
BSAP/SGS	NULL
resulted	NULL
in	NULL
an	NULL
approximately	NULL
twofold	NULL
increase	NULL
in	NULL
promoter	NULL
activity	NULL
relative	NULL
to	NULL
that	NULL
seen	NULL
in	NULL
cells	NULL
cotransfected	NULL
with	NULL
Wp440	NULL
and	NULL
the	NULL
empty	NULL
pSGS	NULL
control	NULL
.	NULL

This	NULL
appears	NULL
to	NULL
reflect	NULL
a	NULL
weak	NULL
promiscuous	NULL
reporter	NULL
activation	NULL
by	NULL
BSAP	NULL
in	NULL
transient	NULL
assays	NULL
because	NULL
similar	NULL
increases	NULL
were	NULL
also	NULL
seen	NULL
with	NULL
Wp	NULL
reporters	NULL
carrying	NULL
mutated	NULL
site	NULL
B	NULL
and	NULL
site	NULL
D	NULL
sequences	NULL
and	NULL
even	NULL
with	NULL
a	NULL
truncated	NULL
Wp	NULL
reporter	NULL
,	NULL
Wp87	NULL
,	NULL
that	NULL
lacks	NULL
both	NULL
UAS1	NULL
and	NULL
UAS2	NULL
regulatory	NULL
sequences	NULL
.	NULL

A	NULL
second	NULL
B-cell	NULL
line	NULL
,	NULL
10464	NULL
TIERNEY	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
-	NULL
soco	NULL
C	NULL
AKATA	NULL
RAMOS	NULL
3	NULL
4000	NULL
§	NULL
£3000	NULL
i	NULL
é	NULL
2000	NULL
{	NULL
k=l	NULL
'	NULL
g	NULL
10007	NULL
H	NULL
0	NULL
;	NULL
2500	NULL
2	NULL
DG75	NULL
K562	NULL
FP	NULL
2000	NULL
6	NULL
¥	NULL
g	NULL
1500	NULL
§	NULL
1000	NULL
g	NULL
&	NULL
so	NULL
o	NULL
1221	NULL
«	NULL
ia	NULL
r¥a	NULL
r¥a	NULL
con	NULL
om	NULL
mo	NULL
g	NULL
g	NULL
=	NULL
-	NULL
tx	NULL
3	NULL
8073	NULL
m	NULL
kbd	NULL
>	NULL
to	NULL
B	NULL
2	NULL
Eo	NULL
f	NULL
m	NULL
m	NULL
m	NULL
m	NULL
B	NULL
-	NULL
«	NULL
&	NULL
DG75	NULL
K562	NULL
&	NULL
&	NULL
fold	NULL
activation	NULL
by	NULL
BSAP	NULL
bo	NULL
to	NULL
o	NULL
3	NULL
2	NULL
4	NULL
o	NULL
5	NULL
wo	NULL
pe	NULL
tog	NULL
§	NULL
o=	NULL
-	NULL
o	NULL
&	NULL
$	NULL
4	NULL
kk	NULL
:	NULL
:	NULL
$	NULL
f	NULL
4g	NULL
&	NULL
&	NULL
&	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Contribution	NULL
of	NULL
BSAP	NULL
to	NULL
Wp	NULL
activation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Effects	NULL
of	NULL
site	NULL
B	NULL
and	NULL
site	NULL
D	NULL
mutations	NULL
on	NULL
Wp	NULL
activity	NULL
in	NULL
B	NULL
and	NULL
non-B	NULL
cells	NULL
.	NULL

Promoter	NULL
activity	NULL
was	NULL
assayed	NULL
by	NULL
quantifying	NULL
luciferase	NULL
expression	NULL
in	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
wild-type	NULL
Wp	NULL
reporter	NULL
(	NULL
Wp440	NULL
)	NULL
,	NULL
a	NULL
truncated	NULL
reporter	NULL
lacking	NULL
both	NULL
UAS1	NULL
and	NULL
UAS2	NULL
sequences	NULL
(	NULL
Wp87	NULL
)	NULL
,	NULL
or	NULL
mutant	NULL
derivatives	NULL
of	NULL
Wp440	NULL
carrying	NULL
Bm	NULL
,	NULL
Dm1	NULL
,	NULL
and	NULL
Dm2	NULL
,	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
(	NULL
Bm+Dm1	NULL
and	NULL
Bm+Dm2	NULL
)	NULL
.	NULL

The	NULL
reported	NULL
luciferase	NULL
values	NULL
(	NULL
relative	NULL
light	NULL
units	NULL
[	NULL
RLU	NULL
]	NULL
)	NULL
are	NULL
means	NULL
+	NULL
standard	NULL
deviations	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Effect	NULL
of	NULL
ectopic	NULL
BSAP	NULL
expression	NULL
on	NULL
Wp	NULL
activity	NULL
in	NULL
B	NULL
and	NULL
non-B	NULL
cells	NULL
.	NULL

Promoter	NULL
activity	NULL
was	NULL
assayed	NULL
by	NULL
quantifying	NULL
luciferase	NULL
expression	NULL
in	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
BSAP	NULL
expression	NULL
vector	NULL
BSAP/pSGS	NULL
and	NULL
wild-type	NULL
or	NULL
mutant	NULL
Wp	NULL
reporters	NULL
as	NULL
in	NULL
panel	NULL
A	NULL
.	NULL

In	NULL
cach	NULL
case	NULL
,	NULL
the	NULL
results	NULL
(	NULL
means	NULL
+	NULL
standard	NULL
deviations	NULL
of	NULL
three	NULL
independent	NULL
experi-ments	NULL
)	NULL
are	NULL
represented	NULL
as	NULL
the	NULL
fold	NULL
activation	NULL
of	NULL
luciferase	NULL
activity	NULL
seen	NULL
in	NULL
cells	NULL
cotransfected	NULL
with	NULL
BSAP/pSG5	NULL
and	NULL
the	NULL
relevant	NULL
Wp	NULL
reporter	NULL
over	NULL
that	NULL
seen	NULL
in	NULL
cells	NULL
cotransfected	NULL
with	NULL
pSGS	NULL
and	NULL
the	NULL
relevant	NULL
reporter	NULL
.	NULL

Akata	NULL
,	NULL
gave	NULL
similar	NULL
results	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
introduction	NULL
of	NULL
a	NULL
BSAP	NULL
expression	NULL
vector	NULL
into	NULL
the	NULL
non-B-cell	NULL
line	NULL
K562	NULL
led	NULL
to	NULL
a	NULL
33-fold	NULL
increase	NULL
in	NULL
wild-type	NULL
Wp440	NULL
activity	NULL
;	NULL
this	NULL
was	NULL
reduced	NULL
to	NULL
approximately	NULL
10-fold	NULL
for	NULL
reporters	NULL
in	NULL
which	NULL
one	NULL
of	NULL
the	NULL
BSAP	NULL
binding	NULL
sites	NULL
was	NULL
inactivated	NULL
and	NULL
was	NULL
further	NULL
reduced	NULL
to	NULL
6-fold	NULL
for	NULL
reporters	NULL
lacking	NULL
both	NULL
binding	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Note	NULL
that	NULL
this	NULL
residual	NULL
BSAP-mediated	NULL
activation	NULL
again	NULL
appeared	NULL
to	NULL
be	NULL
promiscuous	NULL
since	NULL
it	NULL
was	NULL
observed	NULL
even	NULL
with	NULL
the	NULL
minimal	NULL
Wp87	NULL
reporter	NULL
construct	NULL
.	NULL

Parallel	NULL
experiments	NULL
in	NULL
a	NULL
second	NULL
non-B-cell	NULL
line	NULL
,	NULL
CEM	NULL
,	NULL
showed	NULL
a	NULL
similar	NULL
specific	NULL
enhancement	NULL
of	NULL
Wp	NULL
activity	NULL
that	NULL
was	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
BSAP	NULL
binding	NULL
sites	NULL
B	NULL
and	NULL
D	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

DISCUSSION	NULL
EBV	NULL
is	NULL
not	NULL
exclusively	NULL
B	NULL
lymphotropic	NULL
but	NULL
can	NULL
access	NULL
a	NULL
range	NULL
of	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
albeit	NULL
inefficiently	NULL
,	NULL
by	NULL
CR2-depen-dent	NULL
or	NULL
-independent	NULL
routes	NULL
(	NULL
25	NULL
,	NULL
39	NULL
,	NULL
49	NULL
,	NULL
53	NULL
,	NULL
63	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
growth-transforming	NULL
program	NULL
of	NULL
viral	NULL
gene	NULL
expression	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
activated	NULL
in	NULL
these	NULL
other	NULL
environments	NULL
.	NULL

Therefore	NULL
,	NULL
what	NULL
determines	NULL
the	NULL
B-cell	NULL
specificity	NULL
of	NULL
the	NULL
transformation	NULL
process	NULL
at	NULL
a	NULL
postreceptor/postviral	NULL
entry	NULL
stage	NULL
?	NULL

This	NULL
report	NULL
addresses	NULL
what	NULL
may	NULL
be	NULL
one	NULL
of	NULL
the	NULL
central	NULL
aspects	NULL
of	NULL
this	NULL
ques-tion	NULL
,	NULL
namely	NULL
,	NULL
the	NULL
cell	NULL
lineage-specific	NULL
controls	NULL
governing	NULL
the	NULL
activation	NULL
of	NULL
Wp	NULL
,	NULL
the	NULL
viral	NULL
promoter	NULL
that	NULL
initiates	NULL
the	NULL
growth-transforming	NULL
program	NULL
in	NULL
B	NULL
cells	NULL
but	NULL
which	NULL
either	NULL
is	NULL
silent	NULL
or	NULL
shows	NULL
only	NULL
transient	NULL
low-level	NULL
activity	NULL
following	NULL
experimental	NULL
infection	NULL
of	NULL
other	NULL
cell	NULL
types	NULL
.	NULL

The	NULL
first	NULL
set	NULL
of	NULL
experiments	NULL
used	NULL
large	NULL
Wp	NULL
sequence	NULL
probes	NULL
in	NULL
bandshift	NULL
assays	NULL
to	NULL
provide	NULL
a	NULL
comprehensive	NULL
view	NULL
of	NULL
the	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
350	NULL
bp	NULL
of	NULL
Wp	NULL
encompassing	NULL
the	NULL
main	NULL
lineage-independent	NULL
region	NULL
(	NULL
UAS2	NULL
)	NULL
and	NULL
B-cell-specific	NULL
region	NULL
(	NULL
UAS1	NULL
)	NULL
of	NULL
the	NULL
promoter	NULL
.	NULL

The	NULL
only	NULL
binding	NULL
detectable	NULL
within	NULL
UASZ2	NULL
mapped	NULL
to	NULL
the	NULL
known	NULL
YY1	NULL
site	NULL
and	NULL
involved	NULL
two	NULL
complexes	NULL
,	NULL
one	NULL
formed	NULL
by	NULL
YY1	NULL
alone	NULL
(	NULL
6	NULL
)	NULL
and	NULL
a	NULL
larger	NULL
complex	NULL
of	NULL
YY1	NULL
and	NULL
a	NULL
second	NULL
,	NULL
as	NULL
yet	NULL
unidentified	NULL
protein	NULL
which	NULL
is	NULL
presumably	NULL
recruited	NULL
to	NULL
the	NULL
site	NULL
through	NULL
an	NULL
interaction	NULL
with	NULL
YY1	NULL
itself	NULL
.	NULL

Both	NULL
factors	NULL
are	NULL
found	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
lincage-independent	NULL
nature	NULL
of	NULL
UASZ	NULL
.	NULL

Moving	NULL
to	NULL
the	NULL
B-cell-specific	NULL
region	NULL
UAS1	NULL
,	NULL
the	NULL
assays	NULL
identified	NULL
a	NULL
new	NULL
binding	NULL
site	NULL
,	NULL
site	NULL
D	NULL
,	NULL
upstream	NULL
of	NULL
the	NULL
previously	NULL
described	NULL
interactions	NULL
at	NULL
the	NULL
CREB	NULL
site	NULL
(	NULL
27	NULL
)	NULL
and	NULL
at	NULL
the	NULL
adjacent	NULL
sites	NULL
B	NULL
and	NULL
C.	NULL
Most	NULL
importantly	NULL
,	NULL
while	NULL
site	NULL
C	NULL
bound	NULL
ubiquitously	NULL
expressed	NULL
proteins	NULL
,	NULL
both	NULL
site	NULL
B	NULL
and	NULL
the	NULL
new	NULL
site	NULL
D	NULL
bound	NULL
B-cell-specific	NULL
factors	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
main	NULL
thrust	NULL
of	NULL
the	NULL
work	NULL
was	NULL
to	NULL
identify	NULL
these	NULL
UAS1	NULL
binding	NULL
proteins	NULL
and	NULL
assess	NULL
their	NULL
role	NULL
in	NULL
Wp	NULL
activation	NULL
.	NULL

Focusing	NULL
first	NULL
on	NULL
site	NULL
C	NULL
,	NULL
the	NULL
evidence	NULL
from	NULL
bandshift	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
from	NULL
supershift	NULL
assays	NULL
with	NULL
specific	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
,	NULL
and	NULL
from	NULL
mutational	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
strongly	NULL
suggests	NULL
that	NULL
members	NULL
of	NULL
the	NULL
RFX	NULL
family	NULL
of	NULL
proteins	NULL
bind	NULL
at	NULL
this	NULL
site	NULL
and	NULL
that	NULL
this	NULL
interaction	NULL
is	NULL
an	NULL
important	NULL
determinant	NULL
of	NULL
Wp	NULL
activity	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
RFX	NULL
proteins	NULL
are	NULL
a	NULL
novel	NULL
family	NULL
of	NULL
transcriptional	NULL
regulators	NULL
with	NULL
a	NULL
conserved	NULL
76-amino-acid	NULL
DNA	NULL
binding	NULL
domain	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Of	NULL
the	NULL
five	NULL
family	NULL
members	NULL
(	NULL
RFX1	NULL
to	NULL
RFX5	NULL
)	NULL
known	NULL
in	NULL
mice	NULL
and	NULL
humans	NULL
,	NULL
RFX1	NULL
,	NULL
-2	NULL
,	NULL
and	NULL
-3	NULL
can	NULL
bind	NULL
as	NULL
either	NULL
homo-	NULL
or	NULL
heterodimers	NULL
to	NULL
similar	NULL
inverted	NULL
repeat	NULL
sequences	NULL
in	NULL
DNA	NULL
,	NULL
in	NULL
some	NULL
cases	NULL
along	NULL
with	NULL
another	NULL
cellular	NULL
factor	NULL
,	NULL
MIBP1	NULL
.	NULL

The	NULL
present	NULL
antibody	NULL
shift	NULL
assays	NULL
indeed	NULL
suggest	NULL
that	NULL
the	NULL
complexes	NULL
found	NULL
at	NULL
site	NULL
C	NULL
in	NULL
vitro	NULL
predominantly	NULL
contain	NULL
homo-	NULL
and	NULL
heterodimers	NULL
of	NULL
RFX1	NULL
,	NULL
MIBP1	NULL
,	NULL
and	NULL
RFX3	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
similar	NULL
complexes	NULL
have	NULL
been	NULL
observed	NULL
in	NULL
in	NULL
vitro	NULL
binding	NULL
assays	NULL
with	NULL
several	NULL
other	NULL
viral	NULL
enhancer	NULL
sequences	NULL
,	NULL
notably	NULL
from	NULL
cytomegalovirus	NULL
,	NULL
polyoma-virus	NULL
,	NULL
and	NULL
HBV	NULL
,	NULL
and	NULL
in	NULL
the	NULL
latter	NULL
two	NULL
cases	NULL
there	NULL
is	NULL
direct	NULL
functional	NULL
evidence	NULL
that	NULL
such	NULL
binding	NULL
has	NULL
a	NULL
regulatory	NULL
role	NULL
(	NULL
7	NULL
,	NULL
10	NULL
,	NULL
45	NULL
,	NULL
46	NULL
,	NULL
51	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
polyomavirus	NULL
and	NULL
HBV	NULL
enhancers	NULL
,	NULL
where	NULL
activation	NULL
requires	NULL
RFX	NULL
binding	NULL
to	NULL
the	NULL
full	NULL
inverted	NULL
repeat	NULL
sequence	NULL
(	NULL
10	NULL
)	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
only	NULL
the	NULL
5	NULL
'	NULL
half	NULL
of	NULL
Wp	NULL
site	NULL
C	NULL
needs	NULL
to	NULL
be	NULL
conserved	NULL
both	NULL
for	NULL
RFX	NULL
complexes	NULL
to	NULL
form	NULL
and	NULL
for	NULL
optimal	NULL
Wp	NULL
activity	NULL
to	NULL
be	NULL
maintained	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

In	NULL
this	NULL
context	NULL
,	NULL
we	NULL
noted	NULL
that	NULL
IVT	NULL
RFX1	NULL
binds	NULL
to	NULL
Wp	NULL
site	NULL
C	NULL
both	NULL
as	NULL
a	NULL
monomer	NULL
and	NULL
as	NULL
a	NULL
dimer	NULL
(	NULL
H.	NULL
Kirby	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
and	NULL
that	NULL
the	NULL
recently	NULL
published	NULL
structure	NULL
of	NULL
the	NULL
RFX1-DNA	NULL
complex	NULL
(	NULL
17	NULL
)	NULL
suggests	NULL
that	NULL
the	NULL
two	NULL
RFX1	NULL
monomers	NULL
bind	NULL
independently	NULL
to	NULL
their	NULL
cognate	NULL
half	NULL
sites	NULL
.	NULL

In	NULL
the	NULL
in	NULL
vivo	NULL
situation	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
binding	NULL
of	NULL
an	NULL
RFX	NULL
monomer	NULL
to	NULL
the	NULL
5	NULL
'	NULL
half	NULL
of	NULL
site	NULL
C	NULL
either	NULL
is	NULL
itself	NULL
sufficient	NULL
for	NULL
Wp	NULL
activity	NULL
or	NULL
facilitates	NULL
the	NULL
binding	NULL
of	NULL
a	NULL
second	NULL
monomer	NULL
to	NULL
the	NULL
adjacent	NULL
half	NULL
site	NULL
.	NULL

Vor	NULL
.	NULL

74	NULL
,	NULL
2000	NULL
A.	NULL
EBV	NULL
Wp	NULL
B	NULL
cell	NULL
specific	NULL
UAS1	NULL
element	NULL
mrﬁ	NULL
RFX	NULL
BSAP	NULL
CREB	NULL
Wp	NULL
B.	NULL
MHCllp	NULL
T	NULL
``	NULL
110	NULL
RFXS	NULL
CREB	NULL
-	NULL
NFY	NULL
complex	NULL
C.	NULL
HBV	NULL
enh	NULL
I	NULL
Xp	NULL
liver	NULL
specific	NULL
domain	NULL
1374	NULL
``	NULL
``	NULL
HNF3	NULL
HNF4	NULL
RFX	NULL
``	NULL
``	NULL
CREB	NULL
NFI	NULL
RXR	NULL
C/EBP	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Schematic	NULL
representation	NULL
of	NULL
the	NULL
principal	NULL
cis-acting	NULL
functional	NULL
domains	NULL
and	NULL
their	NULL
cognate	NULL
binding	NULL
factors	NULL
at	NULL
the	NULL
EBV	NULL
Wp	NULL
,	NULL
the	NULL
MHCIIp	NULL
,	NULL
and	NULL
HBV	NULL
enh-I	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Factors	NULL
binding	NULL
the	NULL
B-cell-specific	NULL
element	NULL
UAS1	NULL
within	NULL
Wp	NULL
include	NULL
the	NULL
ubiquitously	NULL
expressed	NULL
RFX	NULL
and	NULL
CREB/ATF	NULL
proteins	NULL
and	NULL
the	NULL
B-lineage-restricted	NULL
protein	NULL
BSAP	NULL
;	NULL
sequence	NULL
numbers	NULL
shown	NULL
are	NULL
relative	NULL
to	NULL
the	NULL
Wp	NULL
RNA	NULL
start	NULL
site	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Factors	NULL
binding	NULL
at	NULL
MHCIIp	NULL
include	NULL
ubiquitously	NULL
expressed	NULL
components	NULL
of	NULL
the	NULL
RFX	NULL
complex	NULL
(	NULL
RFX5	NULL
and	NULL
its	NULL
associated	NULL
proteins	NULL
RFX-AP	NULL
and	NULL
RFX-B/ANK	NULL
)	NULL
plus	NULL
ubiquitously	NULL
expressed	NULL
CREB	NULL
and	NULL
NF-Y	NULL
proteins	NULL
,	NULL
binding	NULL
to	NULL
the	NULL
X	NULL
,	NULL
X2BP	NULL
,	NULL
and	NULL
Y	NULL
box	NULL
sequences	NULL
,	NULL
respectively	NULL
(	NULL
32	NULL
,	NULL
36	NULL
)	NULL
;	NULL
sequence	NULL
numbers	NULL
shown	NULL
are	NULL
relative	NULL
to	NULL
the	NULL
MHCIIp	NULL
RNA	NULL
start	NULL
site	NULL
.	NULL

Lincage-restricted	NULL
activity	NULL
of	NULL
MHClIlps	NULL
is	NULL
determined	NULL
by	NULL
expression	NULL
of	NULL
CIITA	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
one	NULL
or	NULL
more	NULL
above	NULL
factors	NULL
,	NULL
leading	NULL
to	NULL
promoter	NULL
activation	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Factors	NULL
binding	NULL
to	NULL
HBV	NULL
enh-I	NULL
include	NULL
ubiquitously	NULL
expressed	NULL
RFX	NULL
,	NULL
CREB	NULL
,	NULL
and	NULL
NF1	NULL
proteins	NULL
,	NULL
plus	NULL
hepatocyte-specific	NULL
HNF3	NULL
,	NULL
HNF4	NULL
,	NULL
RXR	NULL
,	NULL
and	NULL
C/EBP	NULL
proteins	NULL
;	NULL
sequence	NULL
numbers	NULL
refer	NULL
to	NULL
coordinates	NULL
on	NULL
the	NULL
HBV	NULL
genome	NULL
.	NULL

In	NULL
each	NULL
case	NULL
the	NULL
arrow	NULL
denotes	NULL
the	NULL
relevant	NULL
transcription	NULL
start	NULL
site	NULL
;	NULL
note	NULL
that	NULL
Xp	NULL
is	NULL
the	NULL
nearest	NULL
of	NULL
several	NULL
HBV	NULL
promoters	NULL
activated	NULL
by	NULL
HBV	NULL
enh-L	NULL
.	NULL

The	NULL
realization	NULL
that	NULL
site	NULL
C	NULL
binds	NULL
RFX	NULL
proteins	NULL
also	NULL
highlighted	NULL
a	NULL
potential	NULL
parallel	NULL
between	NULL
Wp	NULL
and	NULL
the	NULL
intensively	NULL
studied	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
promoter	NULL
(	NULL
MHCIIp	NULL
)	NULL
(	NULL
32	NULL
)	NULL
.	NULL

As	NULL
illustrated	NULL
diagrammatically	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
an	NULL
NF-Y	NULL
site	NULL
,	NULL
MHCIIp	NULL
possesses	NULL
functionally	NULL
important	NULL
RFX	NULL
and	NULL
CREB	NULL
sites	NULL
(	NULL
usually	NULL
termed	NULL
the	NULL
X	NULL
and	NULL
X2	NULL
boxes	NULL
,	NULL
respectively	NULL
)	NULL
in	NULL
similar	NULL
orientation	NULL
and	NULL
position	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
as	NULL
seen	NULL
in	NULL
Wp	NULL
(	NULL
32	NULL
,	NULL
36	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
MHCIIp	NULL
,	NULL
however	NULL
,	NULL
the	NULL
RFX	NULL
site	NULL
binds	NULL
a	NULL
different	NULL
family	NULL
member	NULL
,	NULL
RFX5	NULL
,	NULL
in	NULL
vivo	NULL
;	NULL
the	NULL
consensus	NULL
motif	NULL
of	NULL
RFX3S	NULL
is	NULL
related	NULL
to	NULL
that	NULL
of	NULL
RFX1	NULL
to	NULL
-3	NULL
but	NULL
differs	NULL
in	NULL
that	NULL
it	NULL
forms	NULL
a	NULL
heterotrimeric	NULL
complex	NULL
with	NULL
two	NULL
other	NULL
ubiquitously	NULL
expressed	NULL
proteins	NULL
,	NULL
RFX-AP	NULL
and	NULL
RFX-B/RFX-ANK	NULL
(	NULL
12	NULL
,	NULL
34	NULL
,	NULL
37	NULL
,	NULL
55	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
lineage	NULL
restriction	NULL
over	NULL
MHC	NULL
class	NULL
II	NULL
gene	NULL
expression	NULL
is	NULL
determined	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
class	NULL
II	NULL
transactivator	NULL
(	NULL
CHTA	NULL
)	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
one	NULL
or	NULL
more	NULL
of	NULL
the	NULL
above	NULL
compo-nents	NULL
,	NULL
leading	NULL
to	NULL
promoter	NULL
activity	NULL
(	NULL
54	NULL
,	NULL
60	NULL
)	NULL
.	NULL

Genetic	NULL
loss	NULL
of	NULL
any	NULL
one	NULL
of	NULL
these	NULL
four	NULL
components	NULL
abrogates	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
and	NULL
is	NULL
manifest	NULL
clinically	NULL
as	NULL
an	NULL
immunodeficiency	NULL
disease	NULL
,	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Evidence	NULL
to	NULL
date	NULL
suggests	NULL
that	NULL
these	NULL
factors	NULL
which	NULL
are	NULL
important	NULL
at	NULL
the	NULL
MHC	NULL
class	NULL
II	NULL
locus	NULL
are	NULL
not	NULL
involved	NULL
in	NULL
Wp	NULL
regulation	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
found	NULL
no	NULL
evidence	NULL
in	NULL
EBV	NULL
PROMOTER	NULL
REGULATION	NULL
BY	NULL
RFX	NULL
AND	NULL
BSAP	NULL
-	NULL
10465	NULL
antibody	NULL
shift	NULL
assays	NULL
for	NULL
RFX-5	NULL
binding	NULL
to	NULL
the	NULL
site	NULL
C	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
and	NULL
transient	NULL
transfection	NULL
assays	NULL
in	NULL
CIITA-deficient	NULL
B-cell	NULL
lines	NULL
showed	NULL
Wp	NULL
to	NULL
be	NULL
fully	NULL
active	NULL
in	NULL
such	NULL
cells	NULL
(	NULL
Kirby	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

A	NULL
number	NULL
of	NULL
other	NULL
RFX-dependent	NULL
genes	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
regulated	NULL
in	NULL
a	NULL
cell-type-specific	NULL
manner	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Most	NULL
interesting	NULL
in	NULL
this	NULL
regard	NULL
is	NULL
HBV	NULL
enh-I	NULL
,	NULL
which	NULL
is	NULL
selectively	NULL
active	NULL
in	NULL
liver	NULL
cells	NULL
.	NULL

Like	NULL
Wp	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
HBV	NULL
enh-I	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
RFX	NULL
and	NULL
CREB	NULL
proteins	NULL
at	NULL
similar	NULL
locations	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
)	NULL
.	NULL

However	NULL
,	NULL
liver-specific	NULL
activity	NULL
requires	NULL
the	NULL
binding	NULL
of	NULL
additional	NULL
proteins	NULL
,	NULL
including	NULL
hepatocyte-specific	NULL
factors	NULL
HNF3	NULL
,	NULL
HNF4	NULL
,	NULL
RXR	NULL
,	NULL
and	NULL
C/EBP	NULL
,	NULL
to	NULL
nearby	NULL
sites	NULL
in	NULL
the	NULL
HBV	NULL
enh-I	NULL
sequence	NULL
(	NULL
18	NULL
,	NULL
20	NULL
,	NULL
51	NULL
)	NULL
.	NULL

The	NULL
present	NULL
work	NULL
reveals	NULL
a	NULL
similar	NULL
situation	NULL
with	NULL
respect	NULL
to	NULL
Wp	NULL
,	NULL
where	NULL
the	NULL
promoter	NULL
's	NULL
preferential	NULL
activity	NULL
in	NULL
B	NULL
cells	NULL
requires	NULL
two	NULL
additional	NULL
sites	NULL
,	NULL
B	NULL
and	NULL
D	NULL
,	NULL
both	NULL
of	NULL
which	NULL
interact	NULL
with	NULL
the	NULL
B-cell-specific	NULL
protein	NULL
BSAP/Pax-5	NULL
.	NULL

BSAP	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
Pax	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
,	NULL
is	NULL
highly	NULL
lineage	NULL
restricted	NULL
in	NULL
its	NULL
expression	NULL
,	NULL
being	NULL
found	NULL
only	NULL
in	NULL
B	NULL
lymphocytes	NULL
,	NULL
in	NULL
the	NULL
developing	NULL
brain	NULL
,	NULL
and	NULL
in	NULL
adult	NULL
testis	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Expression	NULL
in	NULL
the	NULL
B	NULL
lincage	NULL
begins	NULL
in	NULL
the	NULL
earliest	NULL
B-cell	NULL
precursor	NULL
and	NULL
continues	NULL
through	NULL
all	NULL
stages	NULL
of	NULL
differentiation	NULL
except	NULL
the	NULL
end-stage	NULL
plasma	NULL
cell	NULL
(	NULL
5	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
targeted	NULL
gene	NULL
disruption	NULL
in	NULL
mice	NULL
has	NULL
shown	NULL
that	NULL
BSAP	NULL
is	NULL
required	NULL
for	NULL
B-cell	NULL
differentiation	NULL
to	NULL
proceed	NULL
beyond	NULL
the	NULL
pro-B-cell	NULL
stage	NULL
(	NULL
40	NULL
,	NULL
59	NULL
)	NULL
.	NULL

This	NULL
reflects	NULL
a	NULL
key	NULL
role	NULL
for	NULL
BSAP	NULL
as	NULL
a	NULL
determinant	NULL
of	NULL
B-cell	NULL
commitment	NULL
through	NULL
its	NULL
ability	NULL
both	NULL
to	NULL
activate	NULL
B-cell-specific	NULL
genes	NULL
such	NULL
as	NULL
CD19	NULL
and	NULL
to	NULL
suppress	NULL
the	NULL
transcription	NULL
of	NULL
genes	NULL
specific	NULL
for	NULL
other	NULL
hemopoietic	NULL
lineages	NULL
(	NULL
41	NULL
)	NULL
.	NULL

This	NULL
versatility	NULL
as	NULL
a	NULL
transcriptional	NULL
regulator	NULL
appears	NULL
to	NULL
reflect	NULL
the	NULL
existence	NULL
of	NULL
both	NULL
activating	NULL
and	NULL
inhibitory	NULL
domains	NULL
in	NULL
the	NULL
protein	NULL
's	NULL
C-terminal	NULL
regulatory	NULL
region	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Like	NULL
all	NULL
members	NULL
of	NULL
the	NULL
Pax	NULL
family	NULL
,	NULL
BSAP	NULL
binds	NULL
DNA	NULL
through	NULL
a	NULL
paired	NULL
domain	NULL
,	NULL
itself	NULL
composed	NULL
of	NULL
two	NULL
subdomains	NULL
that	NULL
each	NULL
interact	NULL
with	NULL
one	NULL
half	NULL
of	NULL
a	NULL
DNA	NULL
recognition	NULL
motif	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
one	NULL
strong	NULL
subdomain	NULL
,	NULL
half-site	NULL
interaction	NULL
to	NULL
compensate	NULL
for	NULL
weaker	NULL
binding	NULL
at	NULL
the	NULL
other	NULL
half-site	NULL
(	NULL
9	NULL
)	NULL
helps	NULL
to	NULL
explain	NULL
the	NULL
degenerate	NULL
nature	NULL
of	NULL
the	NULL
18-bp	NULL
consensus	NULL
sequence	NULL
for	NULL
BSAP	NULL
binding	NULL
.	NULL

We	NULL
found	NULL
that	NULL
Wp	NULL
site	NULL
D	NULL
and	NULL
particularly	NULL
site	NULL
B	NULL
show	NULL
only	NULL
limited	NULL
homology	NULL
to	NULL
this	NULL
consensus	NULL
,	NULL
yet	NULL
clearly	NULL
both	NULL
bind	NULL
BSAP	NULL
in	NULL
vitro	NULL
,	NULL
with	NULL
the	NULL
interaction	NULL
at	NULL
site	NULL
D	NULL
being	NULL
the	NULL
stronger	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Most	NULL
importantly	NULL
,	NULL
mutations	NULL
in	NULL
site	NULL
B	NULL
and/or	NULL
D	NULL
which	NULL
abrogated	NULL
BSAP	NULL
binding	NULL
substantially	NULL
reduced	NULL
Wp	NULL
activity	NULL
in	NULL
B-cell	NULL
lines	NULL
but	NULL
hardly	NULL
affected	NULL
the	NULL
promoter	NULL
's	NULL
low	NULL
baseline	NULL
activity	NULL
in	NULL
non-B	NULL
cells	NULL
.	NULL

Conversely	NULL
,	NULL
ectopic	NULL
expression	NULL
of	NULL
BSAP	NULL
in	NULL
a	NULL
non-B-cell	NULL
environment	NULL
significantly	NULL
enhanced	NULL
Wp	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
,	NULL
implying	NULL
that	NULL
BSAP	NULL
is	NULL
the	NULL
main	NULL
if	NULL
not	NULL
the	NULL
only	NULL
B-cell-specific	NULL
cellular	NULL
protein	NULL
involved	NULL
in	NULL
Wp	NULL
activation	NULL
.	NULL

It	NULL
has	NULL
to	NULL
be	NULL
stressed	NULL
that	NULL
our	NULL
experiments	NULL
identifying	NULL
roles	NULL
for	NULL
CREB	NULL
,	NULL
RFX	NULL
,	NULL
and	NULL
BSAP	NULL
in	NULL
Wp	NULL
activation	NULL
rely	NULL
on	NULL
transient	NULL
transfection	NULL
assays	NULL
of	NULL
Wp	NULL
reporter	NULL
constructs	NULL
in	NULL
established	NULL
B-cell	NULL
lines	NULL
,	NULL
and	NULL
further	NULL
work	NULL
will	NULL
be	NULL
required	NULL
to	NULL
determine	NULL
how	NULL
many	NULL
of	NULL
these	NULL
regulatory	NULL
controls	NULL
are	NULL
important	NULL
in	NULL
the	NULL
natural	NULL
cellular	NULL
environment	NULL
in	NULL
which	NULL
Wp	NULL
is	NULL
activated	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
in	NULL
mature	NULL
resting	NULL
B	NULL
cells	NULL
.	NULL

Importantly	NULL
,	NULL
however	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
all	NULL
of	NULL
these	NULL
factors	NULL
are	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
and	NULL
are	NULL
therefore	NULL
presumably	NULL
available	NULL
for	NULL
binding	NULL
and	NULL
activation	NULL
of	NULL
Wp	NULL
during	NULL
virus	NULL
infection	NULL
of	NULL
such	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

Note	NULL
also	NULL
that	NULL
these	NULL
factors	NULL
were	NULL
present	NULL
in	NULL
all	NULL
EBV-negative	NULL
and	NULL
EBV-positive	NULL
B-cell	NULL
lines	NULL
tested	NULL
,	NULL
including	NULL
EBV-positive	NULL
BL	NULL
lines	NULL
such	NULL
as	NULL
Akata	NULL
in	NULL
which	NULL
both	NULL
Wp	NULL
and	NULL
Cp	NULL
on	NULL
the	NULL
resident	NULL
viral	NULL
genome	NULL
are	NULL
transcriptionally	NULL
silent	NULL
;	NULL
this	NULL
finding	NULL
is	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
(	NULL
6	NULL
,	NULL
23	NULL
,	NULL
33	NULL
)	NULL
that	NULL
all	NULL
B-cell	NULL
lines	NULL
support	NULL
the	NULL
expression	NULL
of	NULL
transiently	NULL
introduced	NULL
Wp	NULL
reporter	NULL
constructs	NULL
,	NULL
irrespective	NULL
of	NULL
EBV	NULL
status	NULL
.	NULL

Indeed	NULL
,	NULL
in	NULL
cell	NULL
lines	NULL
where	NULL
the	NULL
endogenous	NULL
viral	NULL
Wp	NULL
is	NULL
silent	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
10466	NULL
TIERNEY	NULL
ET	NULL
AL	NULL
.	NULL

that	NULL
the	NULL
promoter	NULL
is	NULL
maintained	NULL
in	NULL
an	NULL
inactive	NULL
state	NULL
by	NULL
CpG	NULL
methylation	NULL
rather	NULL
than	NULL
by	NULL
the	NULL
absence	NULL
of	NULL
any	NULL
essential	NULL
DNA	NULL
binding	NULL
factors	NULL
(	NULL
23	NULL
,	NULL
33	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
this	NULL
work	NULL
provides	NULL
the	NULL
first	NULL
evidence	NULL
for	NULL
the	NULL
coinvolvement	NULL
of	NULL
CREB	NULL
and	NULL
RFX	NULL
family	NULL
members	NULL
with	NULL
BSAP	NULL
in	NULL
promoter	NULL
regulation	NULL
.	NULL

Since	NULL
the	NULL
loss	NULL
of	NULL
a	NULL
binding	NULL
site	NULL
for	NULL
any	NULL
one	NULL
of	NULL
these	NULL
factors	NULL
severely	NULL
impairs	NULL
the	NULL
B-cell-specific	NULL
activity	NULL
of	NULL
Wp	NULL
,	NULL
it	NULL
would	NULL
appear	NULL
that	NULL
transcriptional	NULL
activation	NULL
requires	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
specific	NULL
multiprotein	NULL
complex	NULL
.	NULL

In	NULL
this	NULL
re-gard	NULL
,	NULL
we	NULL
note	NULL
that	NULL
in	NULL
in	NULL
vitro	NULL
bandshift	NULL
assays	NULL
,	NULL
CREB	NULL
,	NULL
RFX	NULL
,	NULL
and	NULL
BSAP	NULL
were	NULL
each	NULL
capable	NULL
of	NULL
binding	NULL
independently	NULL
to	NULL
the	NULL
relevant	NULL
short	NULL
oligonucleotide	NULL
containing	NULL
their	NULL
cognate	NULL
sequence	NULL
as	NULL
well	NULL
as	NULL
to	NULL
longer	NULL
probes	NULL
containing	NULL
all	NULL
three	NULL
sites	NULL
.	NULL

Furthermore	NULL
,	NULL
using	NULL
the	NULL
longer	NULL
probes	NULL
,	NULL
we	NULL
saw	NULL
no	NULL
clear	NULL
evidence	NULL
of	NULL
cooperative	NULL
binding	NULL
as	NULL
reflected	NULL
by	NULL
higher	NULL
complex	NULL
formation	NULL
.	NULL

However	NULL
,	NULL
there	NULL
may	NULL
well	NULL
be	NULL
cooperative	NULL
interactions	NULL
in	NULL
vivo	NULL
that	NULL
stabilize	NULL
the	NULL
multiprotein	NULL
complex	NULL
at	NULL
UAS1	NULL
and/or	NULL
enhance	NULL
its	NULL
engagement	NULL
with	NULL
the	NULL
transcriptional	NULL
ma-chinery	NULL
.	NULL

The	NULL
important	NULL
point	NULL
is	NULL
that	NULL
even	NULL
though	NULL
CREB	NULL
and	NULL
RFX	NULL
factors	NULL
are	NULL
ubiquitously	NULL
expressed	NULL
,	NULL
the	NULL
critical	NULL
requirement	NULL
for	NULL
BSAP	NULL
means	NULL
that	NULL
Wp	NULL
will	NULL
be	NULL
efficiently	NULL
activated	NULL
only	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

In	NULL
the	NULL
infected	NULL
host	NULL
,	NULL
virus	NULL
dissemination	NULL
within	NULL
the	NULL
B-cell	NULL
system	NULL
appears	NULL
to	NULL
require	NULL
a	NULL
period	NULL
of	NULL
virus-driven	NULL
growth	NULL
transformation	NULL
followed	NULL
by	NULL
a	NULL
down-regulation	NULL
of	NULL
the	NULL
transforming	NULL
genes	NULL
,	NULL
thereby	NULL
allowing	NULL
latently	NULL
infected	NULL
cells	NULL
to	NULL
persist	NULL
in	NULL
the	NULL
resting	NULL
state	NULL
.	NULL

This	NULL
tight	NULL
physiological	NULL
control	NULL
might	NULL
well	NULL
be	NULL
lost	NULL
,	NULL
however	NULL
,	NULL
if	NULL
the	NULL
growth-transforming	NULL
program	NULL
were	NULL
to	NULL
be	NULL
activated	NULL
indiscriminately	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
.	NULL

Arguably	NULL
,	NULL
EBV	NULL
has	NULL
evolved	NULL
to	NULL
exploit	NULL
the	NULL
B-cell-restricted	NULL
nature	NULL
of	NULL
BSAP	NULL
,	NULL
possibly	NULL
as	NULL
one	NULL
of	NULL
several	NULL
strategies	NULL
,	NULL
to	NULL
ensure	NULL
that	NULL
viral	NULL
transformation	NULL
is	NULL
initiated	NULL
only	NULL
in	NULL
the	NULL
appropriate	NULL
cell	NULL
environment	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
R.T.	NULL
and	NULL
HK	NULL
.	NULL

contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

We	NULL
thank	NULL
Walter	NULL
Reith	NULL
(	NULL
University	NULL
of	NULL
Geneva	NULL
,	NULL
Geneva	NULL
,	NULL
Switzer-land	NULL
)	NULL
for	NULL
RFX	NULL
antisera	NULL
and	NULL
for	NULL
helpful	NULL
advice	NULL
,	NULL
Andreas	NULL
Reimold	NULL
(	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

for	NULL
the	NULL
BSAP/pSGS	NULL
expression	NULL
construct	NULL
,	NULL
Maria	NULL
Zajac-Kaye	NULL
(	NULL
Naval	NULL
Oncology	NULL
Center	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

for	NULL
MIBP1	NULL
antisera	NULL
,	NULL
and	NULL
Debbie	NULL
Williams	NULL
for	NULL
excellent	NULL
secretarial	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
,	NULL
Lon-don	NULL
,	NULL
United	NULL
Kingdom	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Adams	NULL
,	NULL
B.	NULL
,	NULL
P.	NULL
Dorfler	NULL
,	NULL
A.	NULL
Aguzzi	NULL
,	NULL
Z.	NULL
Kozmik	NULL
,	NULL
P.	NULL
I.	NULL
Maurer-Fogy	NULL
,	NULL
and	NULL
M.	NULL
Busslinger	NULL
.	NULL

1992	NULL
.	NULL

Pax-5	NULL
encodes	NULL
the	NULL
transcription	NULL
factor	NULL
BSAP	NULL
and	NULL
is	NULL
expressed	NULL
in	NULL
B	NULL
lymphocytes	NULL
,	NULL
the	NULL
developing	NULL
CNS	NULL
,	NULL
and	NULL
adult	NULL
testis	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

61589-1607	NULL
.	NULL

2	NULL
.	NULL

Alfieri	NULL
,	NULL
C.	NULL
,	NULL
M.	NULL
Birkenbach	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1991	NULL
.	NULL

Early	NULL
events	NULL
in	NULL
Epstein-Barr	NULL
virus	NULL
infection	NULL
of	NULL
human	NULL
B	NULL
lymphocytes	NULL
.	NULL

Virology	NULL
181:595-608	NULL
.	NULL

3	NULL
.	NULL

Babcock	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
L.	NULL
L.	NULL
Decker	NULL
,	NULL
M.	NULL
Volk	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Thorley-Lawson	NULL
.	NULL

1998	NULL
.	NULL

EBV	NULL
persistence	NULL
in	NULL
memory	NULL
B	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

Immunity	NULL
9:395-404	NULL
.	NULL

4	NULL
.	NULL

Barberis	NULL
,	NULL
A.	NULL
,	NULL
G.	NULL
Superti-Furga	NULL
,	NULL
L.	NULL
Vitelli	NULL
,	NULL
I.	NULL
Kemlar	NULL
,	NULL
and	NULL
M.	NULL
Busslinger	NULL
.	NULL

1989	NULL
.	NULL

Developmental	NULL
and	NULL
tissue-specific	NULL
regulation	NULL
of	NULL
a	NULL
novel	NULL
transcription	NULL
factor	NULL
of	NULL
the	NULL
sea	NULL
urchin	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:663-675	NULL
.	NULL

5	NULL
.	NULL

Barberis	NULL
,	NULL
A.	NULL
,	NULL
K.	NULL
Widenhorn	NULL
,	NULL
L.	NULL
Vitelli	NULL
,	NULL
and	NULL
M.	NULL
Busslinger	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
novel	NULL
B-cell	NULL
lineage-specific	NULL
transcription	NULL
factor	NULL
present	NULL
at	NULL
early	NULL
but	NULL
not	NULL
late	NULL
stages	NULL
of	NULL
differentiation	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

4:849-859	NULL
.	NULL

6	NULL
.	NULL

Bell	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Skinner	NULL
,	NULL
H.	NULL
Kirby	NULL
,	NULL
and	NULL
A.	NULL
Rickinson	NULL
.	NULL

1998	NULL
.	NULL

Characterisation	NULL
of	NULL
regulatory	NULL
sequences	NULL
at	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
BamHI	NULL
W	NULL
promoter	NULL
.	NULL

Virology	NULL
252:149-161	NULL
.	NULL

7	NULL
.	NULL

Blake	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
Niklinski	NULL
,	NULL
and	NULL
M.	NULL
Zajac-Kaye	NULL
.	NULL

1996	NULL
.	NULL

Interactions	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
MIBP1	NULL
and	NULL
RFX1	NULL
with	NULL
the	NULL
EP	NULL
clement	NULL
of	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
enhancer	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:6060-6066	NULL
.	NULL

8	NULL
.	NULL

Cornille	NULL
,	NULL
F.	NULL
,	NULL
P.	NULL
Emery	NULL
,	NULL
W.	NULL
Schiiler	NULL
,	NULL
C.	NULL
Lenoir	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
B.	NULL
P.	NULL
Roques	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1998	NULL
.	NULL

DNA	NULL
binding	NULL
properties	NULL
of	NULL
a	NULL
chemically	NULL
synthesized	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
hRFX1	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

26:2143-2149	NULL
.	NULL

9	NULL
.	NULL

Czerny	NULL
,	NULL
T.	NULL
,	NULL
G.	NULL
Schaffner	NULL
,	NULL
and	NULL
M.	NULL
Busslinger	NULL
.	NULL

1993	NULL
.	NULL

DNA	NULL
sequence	NULL
recognition	NULL
by	NULL
Pax	NULL
proteins	NULL
:	NULL
bipartite	NULL
structure	NULL
of	NULL
the	NULL
paired	NULL
domain	NULL
and	NULL
its	NULL
binding	NULL
site	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:2048-2061	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

David	NULL
,	NULL
E.	NULL
,	NULL
A.	NULL
D.	NULL
Garcia	NULL
,	NULL
and	NULL
P.	NULL
Hearing	NULL
.	NULL

1995	NULL
.	NULL

Interaction	NULL
of	NULL
EF-C/RFX1	NULL
with	NULL
the	NULL
inverted	NULL
repeat	NULL
of	NULL
viral	NULL
enhancer	NULL
regions	NULL
is	NULL
required	NULL
for	NULL
transacti-vation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:8353-8360	NULL
.	NULL

Dorfler	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
M.	NULL
Busslinger	NULL
.	NULL

1996	NULL
.	NULL

C-terminal	NULL
activating	NULL
and	NULL
inhibitory	NULL
domains	NULL
determine	NULL
the	NULL
transactivation	NULL
potential	NULL
of	NULL
BSAP	NULL
(	NULL
Pax-5	NULL
)	NULL
,	NULL
Pax-2	NULL
and	NULL
Pax-8	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:1971-1982	NULL
.	NULL

Durand	NULL
,	NULL
B.	NULL
,	NULL
P.	NULL
Sperisen	NULL
,	NULL
P.	NULL
Emery	NULL
,	NULL
E.	NULL
Barras	NULL
,	NULL
M.	NULL
Zuffery	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1997	NULL
.	NULL

RFXAP	NULL
,	NULL
a	NULL
novel	NULL
subunit	NULL
of	NULL
the	NULL
RFX	NULL
DNA	NULL
binding	NULL
complex	NULL
is	NULL
mutated	NULL
in	NULL
MHC	NULL
class	NULL
II	NULL
deficiency	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

16:1045-1055	NULL
.	NULL

Emery	NULL
,	NULL
P.	NULL
,	NULL
B.	NULL
Durand	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1996	NULL
.	NULL

RFX	NULL
proteins	NULL
,	NULL
a	NULL
novel	NULL
family	NULL
of	NULL
DNA	NULL
binding	NULL
proteins	NULL
conserved	NULL
in	NULL
the	NULL
eukaryotic	NULL
kingdom	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

24:803-807	NULL
.	NULL

Emery	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
Strubin	NULL
,	NULL
K.	NULL
Hofmann	NULL
,	NULL
P.	NULL
Bucher	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
consensus	NULL
motif	NULL
in	NULL
the	NULL
RFX	NULL
DNA	NULL
binding	NULL
domain	NULL
and	NULL
binding	NULL
domain	NULL
mutants	NULL
with	NULL
altered	NULL
specificity	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:4486-4494	NULL
.	NULL

Fahraeus	NULL
,	NULL
R.	NULL
,	NULL
A.	NULL
Jansson	NULL
,	NULL
A.	NULL
Ricksten	NULL
,	NULL
A.	NULL
Sjoblom	NULL
,	NULL
and	NULL
L.	NULL
Rymo	NULL
.	NULL

1990	NULL
.	NULL

Epstein-Barr	NULL
virus-encoded	NULL
nuclear	NULL
antigen	NULL
2	NULL
activates	NULL
the	NULL
viral	NULL
latent	NULL
membrane	NULL
protein	NULL
by	NULL
modulating	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
negative	NULL
regulatory	NULL
element	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:7390-7394	NULL
.	NULL

Fearon	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Carter	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
CD19/CR2/TAPA-1	NULL
complex	NULL
of	NULL
B	NULL
lymphocytes-linking	NULL
natural	NULL
to	NULL
acquired-immunity	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

13:127-149	NULL
.	NULL

Gajiwala	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
H.	NULL
Chen	NULL
,	NULL
F.	NULL
Cornille	NULL
,	NULL
B.	NULL
P.	NULL
Roques	NULL
,	NULL
W.	NULL
Reith	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
and	NULL
S.	NULL
K.	NULL
Burley	NULL
.	NULL

2000	NULL
.	NULL

Structure	NULL
of	NULL
the	NULL
winged-helix	NULL
protein	NULL
hRFX1	NULL
reveals	NULL
a	NULL
new	NULL
mode	NULL
of	NULL
DNA	NULL
binding	NULL
.	NULL

Nature	NULL
403:916-921	NULL
.	NULL

Garcia	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
P.	NULL
Ostapachuk	NULL
,	NULL
and	NULL
P.	NULL
Hearing	NULL
.	NULL

1993	NULL
.	NULL

Functional	NULL
interaction	NULL
of	NULL
nuclear	NULL
factors	NULL
EF-C	NULL
,	NULL
HNF-4	NULL
,	NULL
and	NULL
RXR	NULL
alpha	NULL
with	NULL
hepatitis	NULL
B	NULL
virus	NULL
enhancer	NULL
I.	NULL
J.	NULL
Virol	NULL
.	NULL

67:3940-3950	NULL
.	NULL

Grossman	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
E.	NULL
Johannsen	NULL
,	NULL
X.	NULL
Tong	NULL
,	NULL
R.	NULL
Yalamanchilli	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
transactivator	NULL
is	NULL
directed	NULL
to	NULL
response	NULL
elements	NULL
by	NULL
the	NULL
J	NULL
kappa	NULL
recombination	NULL
signal	NULL
binding	NULL
protein	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:7568-7572	NULL
.	NULL

Guo	NULL
,	NULL
W.	NULL
T.	NULL
,	NULL
K.	NULL
D.	NULL
Bell	NULL
,	NULL
and	NULL
J.	NULL
H.	NULL
Ou	NULL
.	NULL

1991	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
EnhI	NULL
enhancer	NULL
and	NULL
X	NULL
promoter	NULL
complex	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:6686-6692	NULL
.	NULL

Henkel	NULL
,	NULL
T.	NULL
,	NULL
P.	NULL
D.	NULL
Ling	NULL
,	NULL
S.	NULL
D.	NULL
Hayward	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Peterson	NULL
.	NULL

1994	NULL
.	NULL

Mediation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
EBNAZ	NULL
transactivation	NULL
by	NULL
recombination	NULL
signal-bind-ing	NULL
protein	NULL
Jx	NULL
.	NULL

Science	NULL
265:92-95	NULL
.	NULL

Iwama	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Pan	NULL
,	NULL
W.	NULL
Reith	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
D.	NULL
G.	NULL
Tenen	NULL
,	NULL
and	NULL
Z	NULL
.	NULL

Sun	NULL
.	NULL

1999	NULL
.	NULL

Dimeric	NULL
RFX	NULL
proteins	NULL
contribute	NULL
to	NULL
the	NULL
activity	NULL
and	NULL
lineage	NULL
specificity	NULL
of	NULL
the	NULL
interleukin-5	NULL
receptor	NULL
a	NULL
promoter	NULL
through	NULL
activation	NULL
and	NULL
repression	NULL
do-mains	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

19:3940-3950	NULL
.	NULL

Jansson	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Masucci	NULL
,	NULL
and	NULL
L.	NULL
Rymo	NULL
.	NULL

1992	NULL
.	NULL

Methylation	NULL
of	NULL
discrete	NULL
sites	NULL
within	NULL
the	NULL
enhancer	NULL
region	NULL
regulates	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
BamHI	NULL
W	NULL
promoter	NULL
in	NULL
Burkitt	NULL
lymphoma	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:62-69	NULL
.	NULL

Jin	NULL
,	NULL
X.	NULL
W.	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Speck	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
of	NULL
critical	NULL
cis	NULL
elements	NULL
involved	NULL
in	NULL
mediating	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2-dependent	NULL
activity	NULL
of	NULL
an	NULL
enhancer	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
viral	NULL
BemHI	NULL
C	NULL
promoter	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:2846-2852	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
,	NULL
C.	NULL
Rivera	NULL
,	NULL
C.	NULL
Sgadari	NULL
,	NULL
J.	NULL
Franklin	NULL
,	NULL
E.	NULL
Max	NULL
,	NULL
K.	NULL
Bhatia	NULL
,	NULL
and	NULL
G.	NULL
Tosata	NULL
.	NULL

1995	NULL
.	NULL

Infection	NULL
of	NULL
human	NULL
endothelial	NULL
cells	NULL
with	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

173:971-980	NULL
.	NULL

Kieff	NULL
,	NULL
E.	NULL
1996	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
and	NULL
its	NULL
replication	NULL
,	NULL
p.	NULL
2343-2396	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
,	NULL
D.	NULL
M.	NULL
Knipe	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Howley	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Fields	NULL
virology	NULL
.	NULL

Lippincott-Raven	NULL
Press	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pa.	NULL
Kirby	NULL
,	NULL
H.	NULL
,	NULL
A.	NULL
Rickinson	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Bell	NULL
.	NULL

2000	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
BamHI	NULL
W	NULL
promoter	NULL
in	NULL
B	NULL
cells	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
CREB/	NULL
ATF	NULL
factors	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

81:1057-1066	NULL
.	NULL

Knox	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Q.	NULL
X.	NULL
Li	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
,	NULL
and	NULL
L.	NULL
S.	NULL
Young	NULL
.	NULL

1996	NULL
.	NULL

In	NULL
vifro	NULL
production	NULL
of	NULL
stable	NULL
Epstein-Barr	NULL
virus	NULL
positive	NULL
epithelial	NULL
cell	NULL
clones	NULL
which	NULL
resemble	NULL
the	NULL
virus-cell	NULL
interaction	NULL
observed	NULL
in	NULL
nasopharyngeal	NULL
carcinoma	NULL
.	NULL

Virology	NULL
215:40-50	NULL
.	NULL

Knutson	NULL
,	NULL
J.	NULL
C.	NULL
1990	NULL
.	NULL

The	NULL
level	NULL
of	NULL
c-fgr	NULL
RNA	NULL
is	NULL
increased	NULL
by	NULL
EBNA-2	NULL
,	NULL
an	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
required	NULL
for	NULL
B-cell	NULL
immortalization	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64	NULL
:	NULL
2530-2536	NULL
.	NULL

Li	NULL
,	NULL
Q.	NULL
X.	NULL
,	NULL
L.	NULL
S.	NULL
Young	NULL
,	NULL
G.	NULL
Niedobitek	NULL
,	NULL
C.	NULL
W.	NULL
D	NULL
,	NULL
M.	NULL
Birkenbach	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1992	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
infection	NULL
and	NULL
replication	NULL
in	NULL
a	NULL
human	NULL
epithelial	NULL
cell	NULL
system	NULL
.	NULL

Nature	NULL
356:347-350	NULL
.	NULL

Lui	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
B.	NULL
H.	NULL
Lee	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Matthews	NULL
.	NULL

1999	NULL
.	NULL

Involvement	NULL
of	NULL
RFX1	NULL
protein	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
antigen	NULL
promoter	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274:15433-15439	NULL
.	NULL

Mach	NULL
,	NULL
B.	NULL
,	NULL
V.	NULL
Steimle	NULL
,	NULL
E.	NULL
Martinez-Soria	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1996	NULL
.	NULL

Regulation	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
genes	NULL
:	NULL
lessons	NULL
from	NULL
a	NULL
disease	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14:301-331	NULL
.	NULL

Masucci	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
B.	NULL
Contreras-Salazar	NULL
,	NULL
E.	NULL
Ragnar	NULL
,	NULL
K.	NULL
Falk	NULL
,	NULL
J.	NULL
Minarovits	NULL
,	NULL
I.	NULL
Ernberg	NULL
,	NULL
and	NULL
G.	NULL
Klein	NULL
.	NULL

1989	NULL
.	NULL

5-Azacytidine	NULL
up	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
(	NULL
EBNA-2	NULL
)	NULL
through	NULL
EBNA-6	NULL
and	NULL
latent	NULL
membrane	NULL
protein	NULL
in	NULL
the	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
line	NULL
Rael	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3135-3141	NULL
.	NULL

Masternak	NULL
,	NULL
K.	NULL
,	NULL
E.	NULL
Barras	NULL
,	NULL
E.	NULL
Zufferey	NULL
,	NULL
B.	NULL
Conrad	NULL
,	NULL
G.	NULL
Corthals	NULL
,	NULL
R.	NULL
Aebersold	NULL
,	NULL
J.-C.	NULL
Sanchez	NULL
,	NULL
D.	NULL
F.	NULL
Hochstrasser	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1998	NULL
.	NULL

A	NULL
gene	NULL
encoding	NULL
a	NULL
novel	NULL
RFX-associated	NULL
transactivator	NULL
is	NULL
mutated	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
deficiency	NULL
patients	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

20:273-277	NULL
.	NULL

Vor	NULL
.	NULL

74	NULL
,	NULL
2000	NULL
35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

Miyashita	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
B.	NULL
Yang	NULL
,	NULL
G.	NULL
J.	NULL
Babcock	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Thorley-Lawson	NULL
.	NULL

1997	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
site	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
persistence	NULL
in	NULL
vivo	NULL
as	NULL
a	NULL
resting	NULL
B	NULL
cell	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

71:4882-4891	NULL
.	NULL

Moreno	NULL
,	NULL
C.	NULL
,	NULL
G.	NULL
W.	NULL
Beresford	NULL
,	NULL
P.	NULL
Louis-Plence	NULL
,	NULL
A.	NULL
C.	NULL
Morris	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Boss	NULL
.	NULL

1999	NULL
.	NULL

CREB	NULL
regulates	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
in	NULL
a	NULL
CIITA-dependent	NULL
manner	NULL
.	NULL

Immunity	NULL
10:143-151	NULL
.	NULL

Nagarajan	NULL
,	NULL
U.	NULL
M.	NULL
,	NULL
P.	NULL
Louis-Plence	NULL
,	NULL
A.	NULL
DeSandro	NULL
,	NULL
R.	NULL
Nilsen	NULL
,	NULL
A.	NULL
Bushey	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Boss	NULL
.	NULL

1999	NULL
.	NULL

RFX-B	NULL
is	NULL
the	NULL
gene	NULL
responsible	NULL
for	NULL
the	NULL
most	NULL
common	NULL
cause	NULL
of	NULL
the	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
,	NULL
an	NULL
MHC	NULL
class	NULL
II	NULL
immunodeficiency	NULL
.	NULL

Immunity	NULL
10:153-162	NULL
.	NULL

Nemerow	NULL
,	NULL
G.	NULL
,	NULL
C.	NULL
Mold	NULL
,	NULL
V.	NULL
Schwend	NULL
,	NULL
V.	NULL
Tollefson	NULL
,	NULL
and	NULL
N.	NULL
Cooper	NULL
.	NULL

1987	NULL
.	NULL

Identification	NULL
of	NULL
gp350	NULL
as	NULL
the	NULL
viral	NULL
glycoprotein	NULL
mediating	NULL
attachment	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
to	NULL
the	NULL
EBV/C3d	NULL
receptor	NULL
of	NULL
B	NULL
cells	NULL
:	NULL
sequence	NULL
homology	NULL
of	NULL
gp350	NULL
and	NULL
C3	NULL
complement	NULL
fragment	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:1416-1420	NULL
.	NULL

Nishikawa	NULL
,	NULL
J.	NULL
,	NULL
S.	NULL
Imai	NULL
,	NULL
T.	NULL
Oda	NULL
,	NULL
T.	NULL
Kojima	NULL
,	NULL
K.	NULL
Okita	NULL
,	NULL
and	NULL
K.	NULL
Takada	NULL
.	NULL

1999	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
promotes	NULL
epithelial	NULL
cell	NULL
growth	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EBNA2	NULL
and	NULL
LMP1	NULL
expression	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:1286-1292	NULL
.	NULL

Nutt	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
P.	NULL
A.	NULL
Rolink	NULL
,	NULL
and	NULL
M.	NULL
Busslinger	NULL
.	NULL

1997	NULL
.	NULL

Essential	NULL
functions	NULL
of	NULL
PaxS	NULL
(	NULL
BSAP	NULL
)	NULL
in	NULL
pro-B	NULL
cell	NULL
development	NULL
:	NULL
difference	NULL
between	NULL
fetal	NULL
and	NULL
adult	NULL
B	NULL
lymphopoiesis	NULL
and	NULL
reduced	NULL
V-to-DJ	NULL
recombination	NULL
at	NULL
the	NULL
IgH	NULL
locus	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

11:476-491	NULL
.	NULL

Nutt	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
B.	NULL
Heavey	NULL
,	NULL
A.	NULL
G.	NULL
Rolink	NULL
,	NULL
and	NULL
M.	NULL
Busslinger	NULL
.	NULL

1999	NULL
.	NULL

Commitment	NULL
to	NULL
the	NULL
B-lymphoid	NULL
lineage	NULL
depends	NULL
on	NULL
the	NULL
transcription	NULL
factor	NULL
Pax5	NULL
.	NULL

Nature	NULL
401:556-562	NULL
.	NULL

Puglielli	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
M.	NULL
Woisetschlaeger	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Speck	NULL
.	NULL

1996.	NULL
oriP	NULL
is	NULL
essential	NULL
for	NULL
EBNA	NULL
gene	NULL
promoter	NULL
activity	NULL
in	NULL
Epstein-Barr	NULL
virus-immortalized	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:5758-5768	NULL
.	NULL

Qu	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
D.	NULL
T.	NULL
Rowe	NULL
.	NULL

1992	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
gene	NULL
expression	NULL
in	NULL
uncultured	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:3715-3724	NULL
.	NULL

Reimold	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
P.	NULL
D.	NULL
Ponath	NULL
,	NULL
Y.-S.	NULL
Li	NULL
,	NULL
R.	NULL
R.	NULL
Hardy	NULL
,	NULL
C.	NULL
S.	NULL
David	NULL
,	NULL
J.	NULL
L.	NULL
Strominger	NULL
,	NULL
and	NULL
L.	NULL
H.	NULL
Glimcher	NULL
.	NULL

1996	NULL
.	NULL

Transcription	NULL
factor	NULL
B	NULL
cell	NULL
lincage-specific	NULL
protein	NULL
regulates	NULL
the	NULL
gene	NULL
for	NULL
the	NULL
human	NULL
X-box	NULL
binding	NULL
protein	NULL
1	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:393-401	NULL
.	NULL

Reinhold	NULL
,	NULL
W.	NULL
,	NULL
L.	NULL
Emens	NULL
,	NULL
A.	NULL
Itkes	NULL
,	NULL
M.	NULL
Blake	NULL
,	NULL
I.	NULL
Ichinose	NULL
,	NULL
and	NULL
M.	NULL
Zajac-Kaye	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
myc	NULL
intron-binding	NULL
polypeptide	NULL
associates	NULL
with	NULL
RFX1	NULL
in	NULL
vivo	NULL
and	NULL
binds	NULL
to	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
promoter	NULL
region	NULL
,	NULL
to	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
enhancer	NULL
,	NULL
and	NULL
to	NULL
regulatory	NULL
regions	NULL
of	NULL
several	NULL
distinct	NULL
viral	NULL
genes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:3041-3048	NULL
.	NULL

Reith	NULL
,	NULL
W.	NULL
,	NULL
C.	NULL
Ucla	NULL
,	NULL
E.	NULL
Barras	NULL
,	NULL
A.	NULL
Gaud	NULL
,	NULL
B.	NULL
Durand	NULL
,	NULL
C.	NULL
Herrero-Sanchez	NULL
,	NULL
M.	NULL
Kobr	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1994	NULL
.	NULL

RFX1	NULL
,	NULL
a	NULL
transactivator	NULL
of	NULL
hepatitis	NULL
B	NULL
virus	NULL
enhancer	NULL
I	NULL
,	NULL
belongs	NULL
to	NULL
a	NULL
novel	NULL
family	NULL
of	NULL
homodimeric	NULL
and	NULL
heterodimeric	NULL
DNA-binding	NULL
proteins	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:1230-1244	NULL
.	NULL

Ricksten	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Olsson	NULL
,	NULL
T.	NULL
Andersson	NULL
,	NULL
and	NULL
L.	NULL
Rymo	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
5	NULL
'	NULL
flanking	NULL
region	NULL
of	NULL
the	NULL
gene	NULL
for	NULL
Epstein-Barr	NULL
virus-encoded	NULL
nuclear	NULL
antigen	NULL
2	NULL
contains	NULL
a	NULL
cell	NULL
type	NULL
specific	NULL
cis-acting	NULL
regulatory	NULL
element	NULL
that	NULL
activates	NULL
transcription	NULL
in	NULL
transfected	NULL
B-cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

16:8391-8410	NULL
.	NULL

Safrany	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
R.	NULL
P.	NULL
Perry	NULL
.	NULL

1993	NULL
.	NULL

Transcription	NULL
factor	NULL
RFX1	NULL
helps	NULL
control	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
mouse	NULL
ribosomal	NULL
protein-encoding	NULL
rpL30	NULL
by	NULL
binding	NULL
to	NULL
its	NULL
alpha	NULL
clement	NULL
.	NULL

Gene	NULL
32:279-283	NULL
.	NULL

Savard	NULL
,	NULL
M.	NULL
,	NULL
C.	NULL
Bélanger	NULL
,	NULL
M.	NULL
Tardif	NULL
,	NULL
P.	NULL
Gourde	NULL
,	NULL
L.	NULL
Flamand	NULL
,	NULL
and	NULL
J.	NULL
Gosselin	NULL
.	NULL

2000	NULL
.	NULL

Infection	NULL
of	NULL
primary	NULL
human	NULL
monocytes	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

74:2612-2619	NULL
.	NULL

Sengupta	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
M.	NULL
Ehrlich	NULL
,	NULL
and	NULL
B.	NULL
D.	NULL
Smith	NULL
.	NULL

1999	NULL
.	NULL

A	NULL
methylation-respon-sive	NULL
MDBP/RFX	NULL
site	NULL
is	NULL
in	NULL
the	NULL
first	NULL
exon	NULL
of	NULL
the	NULL
collagen	NULL
alpha	NULL
2	NULL
(	NULL
I	NULL
)	NULL
promoter	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274:36649-36655	NULL
.	NULL

Siegrist	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
B.	NULL
Durand	NULL
,	NULL
P.	NULL
Emery	NULL
,	NULL
E.	NULL
David	NULL
,	NULL
P.	NULL
Hearing	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1993	NULL
.	NULL

RFX1	NULL
is	NULL
identical	NULL
to	NULL
enhancer	NULL
factor	NULL
C	NULL
and	NULL
functions	NULL
as	NULL
a	NULL
transactivator	NULL
of	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:6375-6384	NULL
.	NULL

EBV	NULL
PROMOTER	NULL
REGULATION	NULL
BY	NULL
RFX	NULL
AND	NULL
BSAP	NULL
52	NULL
53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

10467	NULL
.	NULL

Sinclair	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
L	NULL
Palmero	NULL
,	NULL
G.	NULL
Paters	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farrell	NULL
.	NULL

1994	NULL
.	NULL

EBNA-2	NULL
and	NULL
EBNA-LP	NULL
co-operate	NULL
to	NULL
cause	NULL
GO	NULL
to	NULL
G1	NULL
transition	NULL
during	NULL
immortalization	NULL
of	NULL
resting	NULL
human	NULL
B	NULL
lymphocytes	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:3321-3328	NULL
.	NULL

Sixbey	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
E.	NULL
H.	NULL
Vesterinen	NULL
,	NULL
J.	NULL
G.	NULL
Nedrud	NULL
,	NULL
N.	NULL
Raab-Traub	NULL
,	NULL
L.	NULL
A.	NULL
Walton	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Pagano	NULL
.	NULL

1983	NULL
.	NULL

Replication	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
human	NULL
epithelial	NULL
cells	NULL
infected	NULL
in	NULL
vitro	NULL
.	NULL

Nature	NULL
306:480-483	NULL
.	NULL

Steimle	NULL
,	NULL
V.	NULL
,	NULL
L.	NULL
A.	NULL
Otten	NULL
,	NULL
M.	NULL
Zufferey	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1993	NULL
.	NULL

Complementation	NULL
cloning	NULL
of	NULL
an	NULL
MHC	NULL
class	NULL
II	NULL
transactivator	NULL
mutated	NULL
in	NULL
hereditary	NULL
MHC	NULL
class	NULL
II	NULL
deficiency	NULL
(	NULL
or	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
)	NULL
.	NULL

Cell	NULL
75:135-146	NULL
.	NULL

Steimle	NULL
,	NULL
V.	NULL
,	NULL
B.	NULL
Durand	NULL
,	NULL
E.	NULL
Barras	NULL
,	NULL
M.	NULL
Zufferey	NULL
,	NULL
M.	NULL
R.	NULL
Hadam	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
novel	NULL
DNA	NULL
binding	NULL
regulatory	NULL
factor	NULL
is	NULL
mutated	NULL
in	NULL
primary	NULL
MHC	NULL
class	NULL
II	NULL
deficiency	NULL
(	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

9:1021-1032	NULL
.	NULL

Sung	NULL
,	NULL
N.	NULL
S.	NULL
,	NULL
S.	NULL
Kenney	NULL
,	NULL
D.	NULL
Gutsch	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Pagano	NULL
.	NULL

1991	NULL
.	NULL

EBNA-2	NULL
transactivates	NULL
a	NULL
lymphoid-specific	NULL
enhancer	NULL
in	NULL
the	NULL
BamHI	NULL
C	NULL
promoter	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:2164-2169	NULL
.	NULL

Tanner	NULL
,	NULL
J.	NULL
,	NULL
J.	NULL
Weiss	NULL
,	NULL
D.	NULL
Fearon	NULL
,	NULL
Y.	NULL
Whang	NULL
,	NULL
and	NULL
E.	NULL
Kief	NULL
.	NULL

1987	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
gp350/220	NULL
binding	NULL
to	NULL
the	NULL
B	NULL
lymphocyte	NULL
C3d	NULL
receptor	NULL
mediates	NULL
adsorp-tion	NULL
,	NULL
capping	NULL
,	NULL
and	NULL
endocytosis	NULL
.	NULL

Cell	NULL
50:203-213	NULL
.	NULL

Tierney	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
N.	NULL
Steven	NULL
,	NULL
L.	NULL
S.	NULL
Young	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1994	NULL
.	NULL

Epstcin-Barr	NULL
virus	NULL
latency	NULL
in	NULL
blood	NULL
mononuclear	NULL
cells	NULL
:	NULL
analysis	NULL
of	NULL
viral	NULL
gene	NULL
transcription	NULL
during	NULL
primary	NULL
infection	NULL
and	NULL
in	NULL
the	NULL
carrier	NULL
state	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:7374-7385	NULL
.	NULL

Urbanek	NULL
,	NULL
P.	NULL
,	NULL
Z.-Q	NULL
.	NULL

Wang	NULL
,	NULL
I.	NULL
Fetka	NULL
,	NULL
E.	NULL
F.	NULL
Wagner	NULL
,	NULL
and	NULL
M.	NULL
Busslinger	NULL
.	NULL

1994	NULL
.	NULL

Complete	NULL
block	NULL
of	NULL
early	NULL
B	NULL
cell	NULL
differentiation	NULL
and	NULL
altered	NULL
patterning	NULL
of	NULL
the	NULL
posterior	NULL
midbrain	NULL
in	NULL
mice	NULL
lacking	NULL
Pax5/BSAP	NULL
.	NULL

Cell	NULL
79:901-912	NULL
.	NULL

Villard	NULL
,	NULL
J.	NULL
,	NULL
A.	NULL
Muhlethaler-Mottet	NULL
,	NULL
S.	NULL
Bontron	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1999	NULL
.	NULL

CIHTA-induced	NULL
occupation	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
promoters	NULL
is	NULL
independent	NULL
of	NULL
the	NULL
cooperative	NULL
stabilization	NULL
of	NULL
the	NULL
promoter-bound	NULL
multiprotein	NULL
complexes	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

11:461-469	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
C.	NULL
D.	NULL
Gregory	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
,	NULL
D.	NULL
Wang	NULL
,	NULL
M.	NULL
Birkenbach	NULL
,	NULL
H.	NULL
Kikutani	NULL
,	NULL
T.	NULL
Kishimoto	NULL
,	NULL
and	NULL
E.	NULL
Kief	NULL
.	NULL

1987	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
specifically	NULL
induces	NULL
expression	NULL
of	NULL
the	NULL
B-cell	NULL
activation	NULL
antigen	NULL
CD23	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:3452-3456	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
S.	NULL
F.	NULL
Tsang	NULL
,	NULL
M.	NULL
G.	NULL
Kurilla	NULL
,	NULL
J.	NULL
L	NULL
Coben	NULL
,	NULL
and	NULL
E.	NULL
Kie	NULL
.	NULL

1990	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
transactivates	NULL
a	NULL
cis-acting	NULL
CD23	NULL
DNA	NULL
element	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4101-4106	NULL
.	NULL

Watry	NULL
,	NULL
D.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Hedrick	NULL
,	NULL
S.	NULL
Siervo	NULL
,	NULL
G.	NULL
Rhodes	NULL
,	NULL
J.	NULL
J.	NULL
Lamberti	NULL
,	NULL
J.	NULL
D.	NULL
Lambris	NULL
,	NULL
and	NULL
C.	NULL
D.	NULL
Tsoukas	NULL
.	NULL

1991	NULL
.	NULL

Infection	NULL
of	NULL
human	NULL
thymocytes	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

173:971-980	NULL
.	NULL

Woisetschlaeger	NULL
,	NULL
M.	NULL
,	NULL
C.	NULL
N.	NULL
Yandava	NULL
,	NULL
L.	NULL
A.	NULL
Furmanski	NULL
,	NULL
J.	NULL
L.	NULL
Strominger	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Speck	NULL
.	NULL

1990	NULL
.	NULL

Promoter	NULL
switching	NULL
in	NULL
Epstein-Barr	NULL
virus	NULL
during	NULL
the	NULL
initial	NULL
stages	NULL
of	NULL
infection	NULL
of	NULL
B	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:1725-1729	NULL
.	NULL

Zajac-Kaye	NULL
,	NULL
M.	NULL
,	NULL
E.	NULL
P.	NULL
Gelmann	NULL
,	NULL
and	NULL
D.	NULL
Levens	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
c-myc	NULL
locus	NULL
of	NULL
a	NULL
Burkitt	NULL
lymphoma	NULL
abolishes	NULL
binding	NULL
of	NULL
a	NULL
nuclear	NULL
protein	NULL
.	NULL

Science	NULL
240:1776-1779	NULL
.	NULL

Zimber-Strobl	NULL
,	NULL
U.	NULL
,	NULL
K.	NULL
O.	NULL
Suentzewich	NULL
,	NULL
G.	NULL
Laux	NULL
,	NULL
D.	NULL
Erik	NULL
,	NULL
M.	NULL
Cordier	NULL
,	NULL
A.	NULL
Calender	NULL
,	NULL
M.	NULL
Billaud	NULL
,	NULL
G.	NULL
Lenoir	NULL
,	NULL
and	NULL
G.	NULL
Bornkamm	NULL
.	NULL

1991	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
activates	NULL
transcription	NULL
of	NULL
the	NULL
terminal	NULL
protein	NULL
gene	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:415-423	NULL
.	NULL

Zimber-Strobl	NULL
,	NULL
U.	NULL
,	NULL
L.	NULL
J.	NULL
Strobl	NULL
,	NULL
C.	NULL
Meitinger	NULL
,	NULL
R.	NULL
Hinrichs	NULL
,	NULL
T.	NULL
Sakai	NULL
,	NULL
T.	NULL
Furukawa	NULL
,	NULL
T.	NULL
Honjo	NULL
,	NULL
and	NULL
G.	NULL
Bornkamm	NULL
.	NULL

1994	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
exerts	NULL
its	NULL
transactivating	NULL
function	NULL
through	NULL
the	NULL
interaction	NULL
with	NULL
recombination	NULL
signal	NULL
binding	NULL
protein	NULL
RBP-J	NULL
kappa	NULL
,	NULL
the	NULL
homologue	NULL
of	NULL
Dro-sophila	NULL
Suppressor	NULL
of	NULL
Hairless	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:4973-4982	NULL
.	NULL

